WO2006053415A1 - Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof - Google Patents
Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof Download PDFInfo
- Publication number
- WO2006053415A1 WO2006053415A1 PCT/CA2004/002007 CA2004002007W WO2006053415A1 WO 2006053415 A1 WO2006053415 A1 WO 2006053415A1 CA 2004002007 W CA2004002007 W CA 2004002007W WO 2006053415 A1 WO2006053415 A1 WO 2006053415A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- family
- plant
- mmp
- skin
- extracts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Definitions
- the invention pertains to the field of dermatology, specifically within the field of dermatological preparations comprising plant extracts.
- the skin is the most environmentally-stressed organ in mammals, particularly in humans. Not only is the skin subjected to germs, toxic chemicals and hostile environments, it is the only organ directly exposed to ultraviolet light (UV). In addition, the vitality of this organ is a consequence of genetic processes, which over time, lead to a decrease in the functionality of the skin. Hence, a variety of dermatological conditions may occur as a result of ongoing intrinsic factors (for example, chronological ageing, disease and allergies) and/or exposure to a number of extrinsic factors (such as infection, trauma, radiation, toxins and steroid use).
- ongoing intrinsic factors for example, chronological ageing, disease and allergies
- extrinsic factors such as infection, trauma, radiation, toxins and steroid use.
- Skin is a highly organized structure consisting of two principal parts.
- the outer thinner part, the epidermis or cuticle, is organised into four ,or five cell layers depending on its location. These layers are the stratum corneum, stratum lucidem (usually only present where the skin is thickened), stratum granulosum, stratum spinosum and stratum basale.
- stratum corneum stratum lucidem (usually only present where the skin is thickened)
- stratum granulosum stratum spinosum
- stratum basale stratum basale.
- the inner, thicker part of the skin, the dermis or true skin is composed of a papillary layer above and a reticular layer below.
- the dermis also comprises blood vessels, nerves, hair follicles and sweat glands.
- the layer below the dermis the hypodermis, comprises mainly loose connective tissue and adipose cells and may be considered part of the skin in that it functions to anchor the epidermis/dermis to the underlying bone and muscle.
- the hypodermis also supplies the dermis with blood vessels and nerves.
- the cells of the skin are generally in contact with a network of large extracellular macromolecules that occupy the spaces in a tissue between the component cells and between adjacent tissues.
- This extracellular matrix functions as a scaffolding on which the cells and tissue are supported and is involved actively in regulating interaction of the cells that contact it.
- the principal macromolecules of the ECM include the collagens (the most abundant proteins in the body) and glycosaminoglycans (complex polysaccharides which are usually bonded to protein and then termed proteoglycans). Additional proteins that may be found in the ECM include elastin, fibronectin and laminin.
- the dermal layer of the skin is composed largely of ECM (or "connective tissue") containing high proportions of collagen and elastin in which cells are embedded.
- Extracellular proteases in particular matrix metalloproteinases (MMPs)
- MMPs matrix metalloproteinases
- An age-related increase in levels of MMPs, in particular MMP-I, -2 and -9, in the skin has been demonstrated (see U.S. Patent Application No. 200100513347).
- Elastic fibers are essential extracellular matrix macromolecules comprising an elastin core surrounded by a mantle of fibrillin-rich microfibrils. These fibers endow connective tissues such as blood vessels, lungs and skin with the critical properties of elasticity and resilience (see review of elastic fibers by Kielty CM et al: J Cell Sci (2002) 115:2817-2828). Exposure to the sun is known to cause disorganization of elastin in the skin known as "elastosis,” which is also a hallmark of skin-ageing.
- Neutrophil elastase has been implicated in elastosis, for example, when compared to normal mice, mice that are deficient in neutrophil elastase are unaffected by exposure to UVB. In addition, an increase in elastase activity has been observed in the skin following chronic UVB irradiation (Tsukahara K et al Biol Pharm Bull 2001;24(9):998-1003). Both a synthetic inhibitor of fibroblast elastase and an extract of Sanguisorba officinalis L. inhibited wrinkle formation and maintained skin elasticity in the rat (Tsukahara K et al Biol Pharm Bull 2001;24(9):998-1003).
- MMPs also play a role in the loss of elastic fibers in skin. Tissue loss during ageing and age-dependent pathologies are the result of a disturbed regulation of proteolytic activities in which elastase-type endopeptidases, especially MMP-2 and -9, are overactivated (Isnard N et al: Biomed Pharmacother. 2002 Jul;56(5):258-64). In addition, gelatinase B (MMP-9) has been shown to degrade fibrillin in human skin tissue sections (Berton A et al, Matrix Biol 2000;19(2):139-148).
- Topical skin applications are known in the art to help shield the skin from the vagaries of the environment.
- Conventional skin protections typically attempt to either protect the skin from UV light (see U.S. Patent No. 5,141,741) or provide additional agents capable of neutralizing free radicals (U.S. Patent No. 6,764,693).
- UV blocking compounds Methods of inhibiting either chronological or photo-ageing of the skin by application of UV blocking compounds in combination with compounds that inhibit MMPs have also been reported (U.S. Patent Nos.
- An object of the invention is to provide plant extracts and dermatological uses thereof.
- a dermatological formulation comprising a physiologically acceptable carrier and an effective amount of one or more plant extracts having extracellular protease inhibiting activity, said plant extract derived from any one of the plants listed in Tables 1, 2, 3, 4 and 5 by solvent extraction, said extracellular protease selected from the group of: matrix metalloprotease-1 (MMP-I), matrix metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9) and human leukocyte elastase (HLE), wherein said extract affects one or more cellular activities in skin cells.
- MMP-I matrix metalloprotease-1
- MMP-2 matrix metalloprotease-2
- MMP-3 matrix metalloprotease-3
- MMP-9 matrix metalloprotease-9
- HLE human leukocyte elastase
- a plant extract having extracellular protease inhibiting activity said plant extract derived by solvent extraction from a plant selected from the group of: Aconitum napellus, Acorus calamus, Alchemilla mollis, Allium cepa, Allium sativum, Allium tuberosum, Ambrosia artemisiifolia, Anethum graveolens, Anthemis tinctoria, Aronia melanocarpa (Michx.) ElL, Arctostaphylos uva-ursi, Aronia x prunifolia, Artemisia dracunculus, Avena sativa, Beta vulgaris, Beta vulgaris L. subsp.
- MMP-I matrix metallo ⁇ rotease-1
- MMP-2 matrix metalloprotease-2
- MMP-3 matrix metalloprotease-3
- MMP-9 matrix metalloprotease-9
- HLE human leukocyte elastase
- the plant extract is derived from a plant selected from the group of: Beta vulgaris L., Brassica oleracea L., Capsicum annuum L, Chenopodium quinoa, Daucus carota L., Geranium x cantabrigiense, Juniperus communis L:, Melilotus alba, Pastinaca sativa L., Potentilla anserina L, Rhus typhina L., Solanum melongena L., Tropaeolum majus L., Vaccinium angustifolium, x Triticosecale spp. and Zea mays L.
- the plant extract is derived from the plant material by extraction with an alcohol, water, an aqueous buffer, or a combination thereof as solvent.
- a plant extract of the invention in the preparation of a dermatological formulation.
- a dermatological formulation of the present invention for the routine care of the skin, hair and/or nails.
- a dermatological formulation of the present invention to improve the health and/or appearance of the skin, hair and/or nails.
- a dermatological formulation of the present invention in the treatment or prevention of a dermatological condition.
- a dermatological formulation of the present invention to attenuate or prevent skin ageing.
- a plant extract of the present invention for the routine care of the skin, hair and/or nails.
- a plant extract of the present invention to improve the health and/or appearance of the skin, hair and/or nails.
- a plant extract of the present invention in the treatment or prevention of a dermatological condition.
- a plant extract of the present invention to attenuate or prevent skin ageing.
- a process for identifying a plant extract suitable for the preparation of a dermatological formulation comprising the steps of: (a) generating a plurality of potential extracts by solvent extraction of plant material; (b) analysing the ability of each of said potential plant extracts to inhibit one or more extracellular protease selected from the group of: matrix metalloprotease-1 (MMP-I), matrix 2004/002007
- MMP-2 metalloprotease-2
- MMP-3 matrix metalloprotease-3
- MMP-9 matrix metalloprotease-9
- HLE human leukocyte elastase
- Figure 1 presents an overview of a procedure that can be followed in accordance with one embodiment of the invention in order to generate plant extracts, each of which is derived from solid plant material;
- Figure 3 presents an overview of a commercial procedure that can be followed to prepare plant extracts based on the procedure of Figure 1 ;
- Figure 4 shows the effect of a plant extract of the invention derived from Rheum rhabarbarum on cord formation, (a) untreated cells; (b) cells treated with a positive control; (c) cells treated with an extract of the invention (IX concentration), and (d) cells treated with an extract of the invention (2X concentration);
- Figure 5 presents an overview of a procedure that can be followed in another embodiment of the invention in order to generate plant extracts, each of which is derived from solid plant material;
- Figure 6 describes in further detail, the procedure of Figure 5;
- Figure 7 depicts the effect of plant extracts of the invention on the viability of human keratinocytes and fibroblasts;
- Figure 8 depicts the effect of plant extracts of the invention on the production of collagen in human dermal fibroblasts.
- Figure 9 depicts the effect of plant extracts of the invention on the release of IL-8 from human skin keratinocytes.
- the present invention provides for dermatological formulations comprising one or more plant extracts that are capable of inhibiting at least one skin extracellular protease (EP).
- skin extracellular protease and “skin EP” refer to the extracellular proteases: matrix metalloprotease-1 (MMP-I), matrix metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9) and human leukocyte elastase (HLE).
- MMP-I matrix metalloprotease-1
- MMP-2 matrix metalloprotease-2
- MMP-3 matrix metalloprotease-3
- MMP-9 matrix metalloprotease-9
- HLE human leukocyte elastase
- the present invention further provides for a rapid method for screening plant extracts to identify those having the above activity that are suitable for incorporation into the dermatological formulations of the invention.
- the invention also provides for the use of plant extracts having the above activity as dermatological agents suitable for the treatment or prevention of various dermatological conditions, including wrinkling or sagging of the skin, irradiation-induced skin and/or hair damage, deepening of skin lines, elastotic changes in the skin, and the like, as well as for the routine care of the skin, hair and/or nails and to improve the health and/or appearance of the skin, hair and nails.
- the present invention additionally provides for novel plant extracts identified by the methods described herein that inhibit one or more skin extracellular proteases, and which are suitable for use as dermatological agents.
- Semi-purified/purified active ingredients i.e. molecules or compounds isolated from a plant extract of the invention and the use of these active ingredients, alone or in combination with an extract, as dermatological agents are also contemplated.
- the integumentary system of a mammal is made up of components (the skin, hair and nails) derived from the ectoderm and subjacent mesoderm.
- Mammalian skin is composed of a number of layers of cells embedded in an extracellular, matrix (the ECM), which provides structure to the skin and comprises a number of polymeric structural components including collagen, elastin and fibronectin. Dispersed within the ECM are various types of cells, including fibroblasts and immune cells, which secrete EPs into the ECM.
- the ECM of the skin is in a constant state of flux, or turnover, which is tightly regulated and mediated in part by the secreted EPs, which are capable of degrading the structural components of the ECM.
- a shift in this turnover to an increased rate in the breakdown of one or more ECM structural components, such as collagen(s) or elastin, results in an increased degradation of the ECM and undesirable structural changes in the skin itself.
- Changes in the structure of the ECM can also affect the hair and nails, which are reliant on the skin for nourishment. Shifts in the balance of ECM turnover can occur as a consequence of a disease condition or of exposure of the skin to harmful elements (such as UV irradiation), or they can occur naturally, for example, as part of the ageing process.
- harmful elements such as UV irradiation
- EP-mediated ECM degradation refers to the breakdown of one or more component of the ECM surrounding the cells of mammalian skin including, for example, collagen, elastin, fibrillin and/or fibronectin.
- Undesirable skin structural changes include, for example, wrinkling and/or sagging of the skin, loss of elasticity, redness, inflammation, formation of lesions, thinning of the epithelium, abnormal migration of cells within the skin (such as that which occurs during angiogenesis or inflammation), or various combinations thereof.
- potential plants is intended to include all species of the Kingdom Plantae, including terrestrial, aquatic or other plants under the Division Chlorophyta, Division Rhodophora, Division Paeophyta, Division Bryophyta and Division Tracheophyta; Subdivision Lycopsida, Subdivision Sphenopsida, Subdivision Pteropsida and Subdivisionspermopsida; Class Gymnospermae, Class Angiospermae, Subclass Dicotyledonidae and Subclass Monocotyledonidae.
- plant material refers to any part or parts of a plant taken either individually or in a group. Examples include, but are not limited to, leaves, flowers, roots, seeds, pods, stems, fruits, seed coats, buds, and other parts of a plant.
- potential extract refers to a composition prepared by contacting plant material with a solvent following the procedures described herein, which has not yet ⁇ been determined to possess inhibitory activity against one or more extracellular protease.
- the potential extract can optionally be subjected to one or more separation and/or purification step .
- plant extract of the invention refers to a composition prepared by contacting plant material with a solvent following the procedures described herein, which demonstrates inhibitory activity against one or more extracellular protease selected from the group of: matrix metalloprotease-1 (MMP-I) 5 matrix metalloprotease-2 (MMP-2), matrix metalloprotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9) and human leukocyte elastase (HLE).
- MMP-I matrix metalloprotease-1
- MMP-2 matrix metalloprotease-2
- MMP-3 matrix metalloprotease-3
- MMP-9 matrix metalloprotease-9
- HLE human leukocyte elastase
- the plant extract can be a primary extract or a substantially pure extract.
- substantially purified and substantially pure when used in reference to a plant extract of the invention refer to an extract that has been subjected to at least one additional treatment subsequent to a first solvent extraction of plant material.
- the present invention provides for primary extracts that result from a "one-step” solvent extraction of plant material followed optionally with a filtration or centrifugation step, and for substantially pure plant extracts that have been subjected to one or more additional steps, such as liquid-liquid extraction, solid-liquid extraction, chromatography, distillation, evaporation, filtration, and the like following the initial extraction process. Both primary extracts and substantially pure extracts are encompassed by the term "plant extracts of the present invention.”
- stressor refers to a factor, such as a physical factor, a chemical compound, or a biological agent that is used to activate a defence response in a plant and thereby elicit production of various chemicals, including extracellular protease inhibitors. Elicitors and inducers are also considered to be stressors.
- an active ingredient when used in reference to an active ingredient, such as a molecule or compound, refers to a form of the active ingredient that has been removed from the plant tissue from which it is derived. Typically, an isolated active ingredient is relatively free of proteins, nucleic acids, lipids, carbohydrates or other materials with which it is naturally associated in a plant.
- An isolated active ingredient may be further purified using routine and well-known methods such as those described herein. As such, an isolated active ingredient of the invention can constitute at least about one or a few percent of a sample, for example, at least about five percent. In one embodiment, the isolated active ingredient constitutes at least about twenty percent of a sample. In another embodiment, the isolated active ingredient is further purified to constitute at least about fifty percent of a sample. In other embodiments, the isolated active ingredient can be further purified to constitute at least about eighty percent, at least about ninety percent and at least about ninety-five percent or more of a sample.
- skin cell refers to a cell normally present within the skin of a mammal.
- skin refers to the epidermis (including the stratum germinativum, stratum spinosum, stratum granulosum, stratum lucidum and stratum corneum), the dermis (including the papillary dermis and the reticular dermis) and the hypodermis.
- skin cells thus includes, but is not limited to, keratinocytes, fibroblasts, endothelial cells (including vascular endothelial cells), basal cells, granular cells, Merkel cells, melanocytes, Langerhans cells, leukocytes, mastocytes, nerve cells, adipose cells and macrophages.
- attenuate means to slow-down, inhibit or prevent.
- cell migration refers to the movement, typically abnormal, of a cell or cells from one locus to another. Examples of cell migration include the movement of cells through the ECM or basal lamina during angiogenesis.
- a “dermatological agent,” as used herein, refers to an extract, compound, composition or formulation intended for the routine care of the integumentary system, for improving the health and/or appearance of the integumentary system or for the treatment or prevention of a dermatological condition.
- skin condition refers to a condition present on one or more of the components of the integumentary system of a subject, i.e. on the skin, hair or nails, caused by ageing or by intrinsic or extrinsic factors.
- treatment refers to an intervention performed with the intention of improving a recipient's status.
- the improvement can be subjective or objective and is related to the amelioration of the symptoms associated with, preventing the development of, or altering the pathology of a condition being treated.
- treatment is used in the broadest sense, and includes the prevention (prophylaxis), moderation, reduction, and curing of a condition at various stages. Prevention of deterioration of a recipient's status is also encompassed by the term.
- Those in need of treatment include those already having the condition as well as those prone to, or at risk of developing, the condition and those in whom the condition is to be prevented.
- ameliorate or “amelioration” includes the arrest, prevention, decrease, or improvement in one or more the symptoms, signs, and features of the condition being treated, both temporary and long-term.
- subject or "patient,” as used herein, refers to a mammal in need of treatment or who would otherwise benefit from the use of a dermatological formulation of the invention.
- the term “about” refers to a +/-10% variation from the nominal value. It is to be understood that such a variation is always included in any given value provided herein, whether or not it is specifically referred to.
- the present invention provides for plant extracts suitable for use as dermatological agents.
- the plant extracts are capable of inhibiting one or more skin extracellular proteases selected from the group of: matrix metalloprotease-1 (MMP-I), matrix metalloprotease-2 (MMP-2), matrix metallo ⁇ fotease-3 (MMP-3), matrix metalloprotease-9 (MMP-9) and human leukocyte elastase (HLE).
- MMP-I matrix metalloprotease-1
- MMP-2 matrix metalloprotease-2
- MMP-3 matrix metallo ⁇ fotease-3
- MMP-9 matrix metalloprotease-9
- HLE human leukocyte elastase
- plant extracts While some plant extracts have previously been identified that inhibit one or more extracellular proteases, the potential for plant extracts that inhibit any one of this particular group of proteases to be effective in various dermatological applications has not previously been established.
- the plant extracts of the invention suitable for use as dermatological agents inhibit at least one of the above listed skin EPs.
- the present invention also contemplates plant extracts that inhibit two or more, three or more, four or more, or all five, of MMP-I, MMP-2, MMP-3, MMP-9 and HLE.
- the plant extract is capable of inhibiting at least MMP-I. In another embodiment, the plant extract is capable of inhibiting at least MMP-2. hi a further embodiment, the plant extract is capable of inhibiting at least MMP-3. In another embodiment, the plant extract is capable of inhibiting at least MMP-9. In another embodiment, the plant extract is capable of inhibiting at least HLE.
- the plant extract is capable of inhibiting at least two of MMP-I, MMP-2, MMP-3, MMP-9 and HLE. In a further embodiment, the plant extract is capable of inhibiting at least three of MMP-I, MMP-2, MMP-3, MMP-9 and HLE.
- the plant extracts may be selected from extracts known in the art and subsequently tested for their ability to inhibit one or more of MMP-I, MMP-2, MMP-3, MMP-9 and/or HLE, or they may be identified using the process described herein.
- the plant extracts are derived from one of the plants listed in Tables 1 to 5.
- the plant extracts are derived from one of the plants listed in Table 6.
- the plant extracts are derived from a plant selected from the group of: Aconitum napellus, Acorus calamus, Alchemilla mollis, Allium cepa, Allium sativum, Allium tuberosum, Ambrosia artemisiifolia, Anethum graveolens, Anthemis tinctoria, Aronia melanocarpa (Michx.) ElL, Arctostaphylos uva-ursi, Aronia x prunifolia, Artemisia dracunculus, Avena sativa, Beta vulgaris, Beta vulgaris L. subsp.
- Vulgare Hypomyces lactifluorum, Juniperus communis L., Lentinus edodes, Lotus corniculatus, Manihot esculenta, Matricaria recutita, Melilotus albus, Melilotus alba Medik, Melissa officinalis, Mentha x piperita, Oenothera biennis, Pastinaca sativa L., Petroselinum crispum, Phaseolus vulgaris, Physalis philadelphica, Phytolacca decandra, Phytolacca decandra syn. P.
- the plant extracts are derived from a plant selected from the group of: Allium cepa, Allium sativum, Ambrosia artemisiifolia, Ambrosia artemisiifolia, Arctostaphylos uva-ursi, Aronia x prunifolia, Artemisia dracunculus, Avena sativa, Beta vulgaris, Beta vulgaris L. subsp. Vulgaris, Brassica napus, Brassica oleracea, Brassica oleracea L. var. italica Plenck, Brassica rapa, Bromus inermis, Capsicum annuum L. var.
- Raphanus raphanistrum Rheum x hybridum, Rhus typhina L., Ribes sylvestre, Rodgersia spp., Rubus occidentalis, Rubus thibetanus, Rumex crispus, Rumex scutatus, Setaria italica, Solanum melongena L, Sorghum conductingna bicolor gr technicum, Stellaria media, Tanacetum cinerariifolium, Taraxacum officinale,
- the plant extract is derived from a plant selected from the group of: Beta vulgaris L., Brassica oleracea L., Capsicum annuum L, Chenopodium quinoa, Daucus carota L., Geranium x cantabrigiense, Juniperus communis L., Melilotus alba, Pastinaca sativa L., Potentilla anserina L., Rhus typhina L., Solanum melongena L., Triticosecale spp., Tropaeolum majus L., Vaccinium angustifolium, and Zea mays L.
- the plant extracts are solvent-based extracts obtained from the selected plant by solvent extraction.
- the solvent can be an aqueous solvent (such as water or a buffer), or it can be a liquid organic compound, or a combination of an aqueous solvent and a liquid organic compound.
- the plant extract is an aqueous, alcoholic or aqueous- alcoholic extract.
- the plant extract is an aqueous, ethanolic, glycolic, aqueous-ethanolic or aqueous-glycolic extract.
- the glycol is butylene glycol.
- the plant extracts are obtained by solvent extraction of plant material from a selected plant.
- the actual extraction process is not critical to the invention, but typically employs as solvent an aqueous solvent (such as water of a buffer), a liquid organic compound, or a combination thereof.
- exemplary liquid organic compounds that can be used as solvents in the extraction process to prepare the plant extracts include, but are not limited to, primary alcohols such as methyl alcohol (methanol), ethyl alcohol (ethanol), 1-propanol and 1-butanol; secondary alcohols such as 2-propanol and 2- butanol; tertiary alcohols such as 2-methyl-2-propanol; liquid polyhydric alcohols such as glycerine and glycols; and other known organic solvents such as acetone, tetrahydrofuran, acetonitrile, 1,4-dioxane, pyridine, dimethylsulfoxide, N,N-dimethyl formamide, acetic acid, diethyl ether,
- the content of the liquid organic compound ranges from about 5% to about 95% by volume.
- the content of the liquid organic compound in the solvent ranges from about 10% to about 90% by volume.
- the content of the liquid organic compound in the solvent ranges from about 20% to about 90% by volume.
- the content of the liquid organic compound in the solvent ranges from about 20% to about 85% by volume.
- the content of the liquid organic compound in the solvent ranges from about 20% to about 50% by volume.
- the content of the liquid organic compound in the solvent ranges from about 50% to about 85% by volume.
- a solvent that is compatible with mammalian skin can be selected.
- solvents include, but are not limited to, water, an aqueous buffer, a combination of water/buffer and a lower alcohol or an anhydrous lower alcohol.
- a lower alcohol refers to an alcohol having 1 to 4 carbon atoms, such as a primary, secondary, tertiary or liquid polyhydric alcohol.
- the solvent is selected from water, a lower alcohol or a combination thereof
- the lower alcohol is selected from the group of: methyl alcohol (methanol), ethyl alcohol (ethanol), 1-propanol, 1-butanol, 2-propanol, 2-butanol, 2-methyl-l- ⁇ ropanol, 2- methyl-2-propanol, glycerine, ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol and 1,3-butylene glycol.
- the lower alcohol content of the solvent typically ranges from about 10% to about 95% by volume. In one embodiment of the present invention, the lower alcohol content of the solvent ranges from about 10% to about 90% by volume. In another embodiment, the lower alcohol content of the solvent ranges from about 15% to about 90% by volume. In a further embodiment, the lower alcohol content of the solvent ranges from about 15% to about 50% by volume. In another embodiment, the lower alcohol content of the solvent ranges from about 50% to about 90% by volume. In an alternate embodiment, the solvent comprises a combination of an aqueous solvent and a lower alcohol, wherein the lower alcohol content is not less than 20% by volume.
- the extraction process entails contacting solid plant material with a solvent with adequate mixing and for a period of time sufficient to ensure adequate exposure of the solid plant material to the solvent such that inhibitory activity present in the plant material can be taken up by the solvent.
- The.plant material employed in the extraction process can be the entire plant, or it can be one or more distinct tissues from a plant, for example, leaves, flowers, roots, seeds, pods, stems, fruits, seed coats, buds, or various combinations thereof.
- the plant material can be fresh, dried or frozen.
- the plant material may be used immediately after harvesting or it can be stored for a period of time prior to being subjected to the extraction process. If the plant material is stored, it can be treated prior to storage, for example, by drying, freezing, lyophilising, or some combination thereof.
- the storage time may be of various durations, for example, the storage period may be between a few days and a few years. Typically storage times range between less than one week to about one year in duration.
- the plant material can be derived from a plant that was subjected to a harvest stress treatment.
- a stress treatment comprises contacting or treating the plant, or material from the plant, with one or more stressor with the aim of inducing or eliciting increased production of one or more chemicals.
- the stressor can be a chemical compound or a physical treatment.
- Examples of chemical stressors include, but are not limited to, organic and inorganic acids including fatty acids, glycerides, phospholipids, glycolipids, organic solvents, amino acids, peptides, monosaccharides, oligosaccharides, polysaccharides, lipopolysaccharides, phenolics, alkaloids, terpenes, terpenoids, antibiotics, detergents, polyamines, peroxides, ionophores, and the like.
- Examples of physical stress treatments include, but are not limited to, ultraviolet radiation, sandblasting, low and high temperature stress, and osmotic stress induced by salt or sugars.
- Nutritional stress is defined as depriving the plant of essential nutrients (e.g.
- the one or more stressor i.e. chemical compound(s), physical treatment(s), or combination thereof
- the one or more stressor may be applied continuously or intermittently to the plant material.
- Various stressors and procedures for stressing plants prior to extract preparation have been described previously (see International Patent Application WO 02/06992) and are suitable for use in the present invention.
- the plant extract is prepared from a plant that has been subjected to a stress treatment.
- the extract is prepared from a plant that has been subjected to one or more chemical stressors.
- the extract is prepared from a plant that has been subjected to one or more chemical stressors selected from the group of: ⁇ -linolenic acid, ⁇ -linolenic acid lower alkyl esters, arachidonic acid and arachidonic acid lower alkyl esters, hi a further embodiment, the extract is prepared from a plant that has been subjected to one or more physical stress, hi yet another embodiment, the extract is derived from an unstressed plant.
- the plant material can be treated prior to the extraction process in order to facilitate the extraction process.
- treatment results in the plant material being fragmented by some means such that a greater surface area is presented to the solvent.
- the plant material can be crushed or sliced mechanically, using a grinder or other device to fragment the plant parts into small pieces or particles, or the plant material can be frozen in liquid nitrogen and then crushed or fragmented into smaller pieces.
- the amount of the solvent used in the extraction can range from about IX to about IOOX (mass/mass) that of the solid plant material, hi one embodiment of the present invention, the amount of solvent used in the extraction process ranges from about IX to about 5OX (mass/mass) that of the solid plant material.
- a variety of conditions can be employed for the extraction process.
- the extraction procedures are conducted over a period of time between about 10 minutes and about 24 hours at a temperature between about 4 0 C and about 5O 0 C.
- temperatures between about 4 0 C and about 9O 0 C, for example between about 4 0 C and about . 7O 0 C can be employed.
- extraction time may be varied depending on other extraction conditions, for example the extraction time can range from several minutes to several hours.
- Adequate contact of the solvent with the plant material can be encouraged by shaking the suspension.
- an extraction device equipped with, for instance, a stirring machine can be employed which may improve the extraction efficiency.
- the extraction can be carried out at ordinary pressure, under pressure or at reduced pressure established by, for example, aspiration.
- Appropriate extraction conditions can readily be determined or selected by one skilled in the art taking into consideration the production conditions such as production facilities and yields.
- the liquid fraction (the primary plant extract) can be separated from the solid (insoluble) matter. Separation of the liquid and solid fractions can be achieved by one or more standard separation processes known to those skilled in the art, such as various centrifugation or filtration processes.
- the primary extract can be subjected to one or more additional steps to further purify the extract.
- the primary extract may be subjected to solid- liquid extraction, liquid-liquid extraction, solid-phase extraction (SPE), membrane filtration, ultrafiltration, dialysis, electrophoresis, solvent concentration, centrifugation, ultracentrifugation, liquid or gas phase chromatography (including size exclusion, affinity, etc.) with or without high pressure, lyophilisation, evaporation, precipitation with various "carriers" (including PVPP, carbon, antibodies, and the like), the use of supercritical fluids (such as CO 2 ), or various combinations thereof to provide a substantially pure extract.
- the plant extract can be tested for its ability to inhibit one or more skin EPs selected from the group of: MMP-I, MMP-2, MMP-3, MMP-9 and HLE, using a variety of techniques known in the art including, but not limited to, those described herein.
- a plant extract that decreases the activity of an EP by at least 20% is considered to be capable of inhibiting the activity of that protease.
- a plant extract that inhibits the activity of one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE by at least 20% is considered to be an extract of the invention.
- the plant extract inhibits the activity of one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE by at least 30%. In another embodiment, the plant extract inhibits the activity of one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE by at least 40%. In a further embodiment, the plant extract inhibits the activity of one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE by at least 45%. In another embodiment, the plant extract inhibits the activity of one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE by at least 50%.
- the extract can be tested against an individual skin EP or against a panel comprising two or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE.
- Proteolytic Enzymes Aspartic Acid and Metallopeptidases, New York: Academic Press, 1995, 248: 470), including the gelatineolytic assay (which is based on the degradation of radio-labelled type I collagen), the zymography assay (which is based on the presence of negatively- stained bands following electrophoresis through substrate-impregnated SDS polyacrylatnide gels) and a microtitre plate assay developed by Pacmen et al, (Biochem. Pharm. (1996) 52:105-111).
- FACS fluorescent activated substrate conversion
- the extract may be tested against one or more EPs in a sequential fashion or it may be tested against a plurality, or array, of skin EPs simultaneously.
- the assays may be adapted to high throughput as is known in the art in order to facilitate simultaneous testing of an extract against a plurality of skin EPs.
- the assays can be conducted using purified or semi-purified EPs. Methods of isolating and purifying EPs are well known in the art. In addition, many EPs are commercially available (for example, from Sigma-Aldrich, St. Louis, MO and Calbiochem, San Diego, CA).
- the ability of the extracts to inhibit the activity of skin EPs can be
- a cell culture is contacted with an appropriate amount of the extract. After an appropriate period of time, the cells are extracted, centrifuged and the proteolytic activity in the supernatant is measured. This method is useful in determining the ability of an extract to inhibit a set of EPs secreted by a particular cell line or combination of cell lines.
- assays can be conducted with cell lines derived from mammalian skin, such as keratinocytes or fibroblasts. . Inhibition of EP Activity in Skin Models
- the extracts may be tested in an appropriate skin model for their ability to inhibit one or more of MMP-I, MMP- 2, MMP-3, MMP-9 and HLE.
- an in vitro human skin model can be employed to test the extract(s).
- Such models are typically constructed from human fibroblasts and keratinocytes by first forming a gel comprising human dermal fibroblasts and collagen. Cell culture medium is added and the gel incubated for a sufficient number of days to allow for fibroblast proliferation, and for collagen and protease synthesis and secretion into the gel.
- donor- matched human epidermal keratinocytes in a biological medium are gently pipetted onto the gel and allowed to establish a confluent layer on its surface.
- the test plant extract is added and after a suitable incubation period (for example, between 6 and 24 hours), the gels are extracted and centrifuged and the proteolytic activity in the supernatant is assayed.
- Immune cells can also be added to the above skin model in order to provide a source of elastase enzymes.
- Other examples of skin models are provided in the art, for example, see U.S. Patent No. 6,079,415 and references therein.
- the ability of the extracts to inhibit skin EP activity may be assessed in vzvo using various standard techniques.
- the ability of the extracts to inhibit protease activity can be determined in animal models or human volunteers.
- An example of a suitable animal model would be a skh-1 mouse or nude mouse or rat that is treated with an extract of the invention and then exposed to UV radiation (see, Nishimori et al. (2001) J. Invest. Dernatol. 117:1458-1463). UV radiation is known to increase the level of activity of certain MMPs (see, for example, U.S. Patent No. 6,130,254).
- Skin biopsies are taken from the animal and the amount of EP activity in the biopsied sample can be measured using standard techniques as an indication of the inhibitory activity of the test extract. Human trials may also be used to evaluate the ability of an extract to inhibit EP activity in the skin.
- skin biopsies can be taken from adult volunteers exposed to UV radiation and treated prior to or after UV exposure with an extract. The biopsiy samples can be assessed for EP activity and compared to an appropriate control (for example, skin biopsies from individuals treated with a control compound or untreated individuals).
- an appropriate control for example, skin biopsies from individuals treated with a control compound or untreated individuals.
- elderly individuals for example, those over 80 years of age could be used as volunteers for the trials without the requirement for UV exposure.
- the samples are typically flash frozen, mechanically ground and/or homogenised. After centrifugation, the supernatants are isolated and used to assess EP activity in assays such as those outlined above.
- the selected plant extracts are capable of affecting one or more cellular activity of skin cells in a beneficial manner.
- the ability of plant extracts to affect one or more cellular activities in skin cells can be assessed in vitro using one, or a combination, of standard techniques known in the art.
- Cellular activities in skin cells that can be assessed in vitro include, but are not limited to, the breakdown of a structural component of the ECM, such as collagen, fibronectin, fibrillin and/or elastin; cell migration; collagen production; UV-induced extracellular protease activity and fractional forces generated by fibroblasts; response to oxidative stresses, inhibition of release of IL-8 or other cytokines, response to induced apoposis, wound healing.
- the ability of the extracts of the invention to attenuate the breakdown of one or more ECM component can be assessed in vitro using skin models such as those described above.
- the gels can be extracted and assayed for the loss of one or more structural components of the ECM, such as elastin, ⁇ collagen, fibronectin and/or fibrillin.
- the gels can be assayed for the presence of fragments of elastin, collagen, fibronectin and/or fibrillin using standard techniques as an indication of the breakdown of these components.
- Elastin for example, can be quantitated biochemically as desmosine or visualized histologically (Starcher B and Conrad M: Ciba Found Symp. (1995) 192:338-46).
- confocal microscopy can be used in visualise the dermal microfibrillar network (Watson RE et al: J Invest Dermatol. (1999) 112(5):782-7).
- Intact elastin and elastin fragments can also be measured by immunoblotting (Sakuraoka K et al: J Dermatol Sd (1996) 12(3):232-237).
- Biochemical and/or immunochemistry methods can be used to assess changes in the amount of collagen in the gels. Ultrastructural methods can also be used to assess changes in the amount of collagen in the gels (Fligiel SE et al: J Invest Dermatol. (2003) 120(5):842-8). Type I collagen, the most abundant extracellular matrix protein deposited in cutaneous involvement, can be measured using the method described by Allanore Y et al (J Rheumatol. (2003) 30(l):68-73).
- Quantitative reverse transcriptase-polymerase chain reaction analysis can be used to determine the presence of dermal elastosis, diminished fibrillin and type VII collagen expression (Bosset S et al: Br J Dermatol. (2003) 148(4):770-8).
- an extract to inhibit migration of cells can be assessed in vitro using standard cell migration assays.
- assays are conducted in multi-well plates, the wells of the plate being separated by a suitable membrane into top and bottom sections.
- the membrane is coated with an appropriate compound, the selection of which is dependent on the type of cell being assessed and can be readily determined by one skilled in the art. Examples include collagen, gelatinee or Matrigel for endothelial cells.
- An appropriate chemo-attractant such as EGM-2, IL-8, ⁇ FGF, ⁇ FGF and the like, is added to the bottom chamber as a chemo-attractant.
- An aliquot of the test cells together with the extract are added to the upper chamber. Typically various dilutions of the extract are tested.
- the membrane is rinsed, fixed and stained. The cells on the upper side of the membrane are wiped off, and then randomly selected fields on the bottom side are counted.
- Inhibition of cell migration can also be assessed using the cord formation assay.
- endothelial cells with or without plant extract are plated onto Matrigel and incubated under appropriate conditions. After a suitable period of time (for example, between 18 and 24 hours), migration of cells is assessed by visual inspection to determine whether the cells have formed into cords.
- Suitable endothelial cell lines include, but are not limited to, human umbilical vein endothelial cells (HUVECs), bovine aortic endothelial cells (BAECs), human coronary artery endothelial cells (HCAECs), bovine adrenal gland capillary endothelial cells (BCE) and vascular smooth muscle cells.
- HUVECs can be isolated from umbilical cords using standard methods (see, for example, Jaffe et al. (1973) J. CUn. Invest. 52: 2745), or they can be obtained from the ATCC or various commercial sources, as can other suitable endothelial cell lines.
- the effect of the plant extracts on collagen I production in the skin cells can be assessed, for example, using immunochemical methods.
- One exemplary method involves measuring the release of the procollagen type I C-peptide (PIP) in skin cells treated with the extract and comparing this to the amount of PIP released by untreated controls and/or controls treated with a compound known to affect collagen production.
- ELISA kits suitable for assaying PIP are commercially available (for example from Takara Minis Bio, Madison, WI). As PIP is cleaved off the procollagen molecule during formation of the collagen triple helix, the amount of this peptide released by the skin cells is stoichiometrically proportional to the amount of collagen synthetized.
- UV-induced extracellular protease activity can be assessed by irradiating cultures of skin cells with UVA light and then treating the irradiated cells with the extract.
- the extract can be added to the cells prior to irradiation to assess the prophylactic effect of the extract. After a suitable period of incubation in an appropriate medium, supernatants can be removed from the cells and assayed for proteolytic activity as described above. Results can be compared to untreated cells and/or cells treated with a compound known to affect UV-induced protease activity.
- Skin cells suitable for use in the above assays include human dermal fibroblasts, keratinocytes, melanocytes, Langerhans cells, cells of the hair follicle and cells of the immune system which produce proteases, including leukocytes, macrophages and lymphocytes.
- MMPs may act to extend anchoring of fibroblasts on the extracellular matrix, resulting in greater fibroblast tractional forces. Accordingly, the effect of the plant extracts on the tractional forces generated by fibroblasts can be assayed.
- This assay employs a model comprising fibroblasts embedded in a collagen matrix to create a derm-like environment.
- Such a model can be prepared by adding fibroblasts to a solution of collagen I in medium and then allowing the collagen to polymerize to form a gel. After an appropriate incubation period, the derm-like gel is treated with an extract and the amount of contraction measured over a period of time, for example, several days.
- the amount of contraction can be assessed for example, by digitally photographing the gel at various time points and calculating the gel area using appropriate software. The amount of contraction can be compared to untreated control gels and/or gels treated with a compound known to affect fibroblast tractional forces.
- the plant extracts may undergo additional testing if desired.
- the ability of the plant extracts to affect one or more cellular activity of skin cells can be assessed in vivo and/or the plant extracts may be submitted to testing on human volunteers to assess their ability to exert the desired dermatological effect(s).
- the plant extracts may also undergo one or more safety, stability and/or bioavailability test prior to testing on human volunteers.
- Degeneration of the ECM in particular due to the breakdown of collagen and/or elastin, can be assessed in skin biopsies, for example, by histological examination of skin tissue after treatment with the extract. Methods described above for the determination of the breakdown of one or more structural components of the ECM can also be used on the biopsied samples. Histology can also be used to determine abnormal cell migration.
- Skin changes such as wrinkling and/or sagging, reddening, formation of lesions, abnormal pigmentation and the like, can be assessed by visual examination.
- the effect of the plant extract on the skin can be evaluated by formulating the extract such that it is suitable for external application to the skin and susequently sensory tests can be conducted on the formulation using by a panel of human volunteers.
- a sensory test typically involves application of the formulation to the skin of the panelists on a regular basis, such as once or twice a day, over a period of several weeks.
- the effect of the formulation on the skin can be evaluated by inspecting the skin of the panelists and assessing visually the skin characteristic or charcteristics being investigated, for example, the tenseness and gloss of the skin, a decrease of any wrinkles, sags, reddening, lesions and/or abnormal pigmentation.
- Erythema in skin samples can be determined, for example, using commercially available chromameter.
- the ability of the plant extracts to reduce inflammation in the skin can also be assessed in human volunteers using standard techniques, including visual inspection.
- the ability of the plant extract to inhibit endothelial cell migration can also be assessed in vivo, using standard techniques such as the CAM assay (see Brooks et al, in Methods in Molecular Biology, Vol. 129, pp. 257-269 (2000), ed. A.R. Howlett, Humana Press Inc., Totowa, NJ; Ausprunk et al, (1975) Am. J. Pathol, 79:597-618; Ossonski et al, (1980) Cancer Res., 40:2300-2309), the Matrigel plug assay (see, for example, Passaniti, et al.,( ⁇ 992) Lab. Invest.
- the CAM assay see Brooks et al, in Methods in Molecular Biology, Vol. 129, pp. 257-269 (2000), ed. A.R. Howlett, Humana Press Inc., Totowa, NJ; Ausprunk et al, (1975) Am. J. Pathol,
- the CAM assay measures neovascularization of whole tissue, wherein chick embryo blood vessels grow into the CAM or into the tissue transplanted on the CAM, and is a well-recognised assay model for in vivo angiogenesis.
- the Matrigel plug assay involves introducing an extract into cold liquid Matrigel which, after subcutaneous injection into a suitable animal model, solidifies and permits penetration by host cells and the formation of new blood vessels. After a suitable period of time, the animal is sacrificed, the Matrigel plug is recovered and angiogenesis is assessed in the Matrigel plug by measuring haemoglobin or by scoring selected regions of histological sections for vascular density.
- the corneal micropocket assay involves preparing pellets from a sterile hydron polymer containing a suitable amount of the extract. The pellets are surgically implanted into corneal stromal micropockets created at an appropriate distance medial to the lateral corneal limbus of a test animal. Angiogenesis can be quantitated at various times after pellet implantation through the use of stereomicroscopy. Typically, the length of neo vessels generated from the limbal vessel ring toward the centre of the cornea and the width of the neovessels are measured.
- the plant extracts of the invention may be submitted to other standard tests to evaluate safety, cytotoxicity, stability, bioavailability and the like. Exemplary tests to determine the cytotoxicity of the extracts and their potential to induce cytokine release are described herein (see Examples X and XIII).
- an extract to penetrate the skin can be assessed, for example, by in vitro release tests (see, for example, the U.S. Center for Drug Evaluation and Research guidance document entitled "Guidance for Industry. Nonsterile Semisolid Dosage Forms. Scale-up and postapproval changes: in vitro release testing and in vivo bioequivalence documentation").
- in vitro release tests see, for example, the U.S. Center for Drug Evaluation and Research guidance document entitled "Guidance for Industry. Nonsterile Semisolid Dosage Forms. Scale-up and postapproval changes: in vitro release testing and in vivo bioequivalence documentation").
- open chamber diffusion cell such as a Franz cell
- the test extract is placed on the upper side of the membrane and kept occluded to prevent solvent evaporation and compositional changes.
- a receptor fluid such as aqueous buffer or hydro-alcoholic medium, is placed on the other side of the membrane in a receptor cell.
- Diffusion of the active component across the membrane is monitored by assay of sequentially collected samples of the receptor fluid.
- the assay could comprise, for example, testing the ability of the collected sample to inhibit EP activity.
- the membrane can be a synthetic membrane, for example polysulphone, cellulose acetate or nitrate, or polytetrafluoroethylene, or it can be a skin sample, such as a sample taken from a cadaver.
- a selected extract may need to meet certain criteria in order to meet regulatory requirements for human use. , Conducting tests such as those described above, therefore, allows the suitability of an extract for human use to be assessed.
- the present invention also provides for active ingredients isolated from the plant extracts of the invention.
- an "active ingredient” is a compound or molecule that is capable of inhibiting one or more skin EPs selected from the group of: MMP-I 5 MMP-2, MMP-3, MMP-9 and HLE.
- the active ingredient may be proteinaceous or non-proteinaceous. Isolated active ingredients can be tested for their ability to inhibit one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE using the procedures described above.
- Solid-liquid extraction means include the use of soxhlet extractors, vortex shakers, ultrasounds and other means to enhance extraction, as well as recovery by filtration, centrifugation and related methods as described in the literature (see, for example, R. J. P. Cannell, Natural Products Isolation, Humana Press, 1998).
- solvents that may be used include, but are not limited to, hydrocarbon solvents, chlorinated solvents, organic esters, organic ethers, alcohols, water, and mixtures thereof.
- the use of supercritical solvents is also contemplated and includes the use of modifiers such as those described in V. H. Bright ⁇ Supercritical Fluid Technology, ACS Symp. Ser. Vol. 488, ch. 22, 1999).
- Liquid-liquid extraction means include the use of various mixtures of solvents known in the art, including solvents under supercritical conditions.
- Typical solvents include, but are not limited to, hydrocarbon solvents, chlorinated solvents, organic esters, organic ethers, alcohols, water, various aqueous solutions, and mixtures thereof.
- the liquid-liquid extraction can be effected manually, or it can be semi-automated or completely automated, and the solvent can be removed or concentrated by standard techniques in the art (see, for example, S. Ahuja, Handbook of Bioseparations, Academic Press, 2000).
- Solid-phase extraction (SPE) techniques include the use of cartridges, columns or other devices known in the art.
- the sorbents that may be used with such techniques include, but are not limited to, silica gel (normal phase), reverse-phase silica gel (modified silica gel), ion-exchange resins, and fluorisil.
- the invention also includes the use of scavenger resins or other trapping reagents attached to solid supports derived from organic or inorganic macromolecular materials to remove selectively active ingredients or other constituents from the extracts.
- Membrane, reverse osmosis and ultrafiltration means include the use of various types of membranes known in the art, as well as the use of pressure, vacuum, centrifugal force, and/or other means that can be utilised in membrane and ultrafiltration processes (see, for example, S. Ahuja, Handbook of Bioseparations, Academic Press, 2000).
- Dialysis means include membranes having a molecular weight cut-off varying from less than about 0.5 KDa to greater than about 50 KDa.
- the invention also covers the recovery of active ingredients from either the dialysate or the retentate by various means known in the art including, but not limited to, evaporation, reduced pressure evaporation, distillation, vacuum distillation, and lyophilization.
- Chromatographic means include various means of carrying out chromatography known by those skilled in the art and described in the literature (see, for example, G. Sofer, L. Hagel, Handbook of Process Chromatography, Academic Press, 1997). Examples include, but are not limited to, regular column chromatography, flash chromatography, high performance liquid chromatography (HPLC), medium pressure liquid chromatography (MPLC), supercritical fluid chromatography (SFC), countercurrent chromatography (CCC), moving bed chromatography, simulated moving bed chromatography, expanded bed chromatography, and planar chromatography.
- HPLC high performance liquid chromatography
- MPLC medium pressure liquid chromatography
- SFC supercritical fluid chromatography
- CCC countercurrent chromatography
- moving bed chromatography simulated moving bed chromatography
- expanded bed chromatography and planar chromatography.
- sorbents examples include, but are not limited to, silica gel, alumina, fluorisil, cellulose and modified cellulose, various modified silica gels, ion-exchange resins, size exclusion gels and other sorbents known in the art (see, for example, T. Hanai, HPLC: A Practical Guide, RSC Press, UK 1999).
- the present invention also includes the use of two or more solvent gradients to effect the fractionation, partial purification, and/or purification of the active ingredients by chromatographic methods.
- solvents examples include, but are not limited to, hexanes, heptane, pentane, petroleum ethers, cyclohexane, heptane, diethyl ether, methanol, ethanol, isopropanol, propanol, butanol, isobutanol, tert-butanol, water, dichloromethane, dichloroethane, ethyl acetate, tetrahydrofuran, dioxane, tert-butyl methyl ether, acetone, and 2-butanone.
- water or an aqueous phase it may contain varying amounts of inorganic or organic salts, and/or the pH may be adjusted to different values with an acid or a base such that fractionation and/or purification is enhanced.
- the present invention includes the use of various forms of this type of chromatography including, but not limited to, one- and two dimension thin-layer chromatography (ID- and 2D-TLC), high performance thin- layer chromatography (HPTLC), and centrifugal thin-layer chromatography (centrifugal TLC).
- ID- and 2D-TLC one- and two dimension thin-layer chromatography
- HPTLC high performance thin- layer chromatography
- centrifugal thin-layer chromatography centrifugal TLC
- the present invention includes the use of manual, semi-automated, and automated systems, and the use of various solvents and solvent combinations necessary to effect fractionation and/or purification of active ingredients (see, for example, W. D. Conway, R. J. Petroski, Modern Countercurrent Chromatography, ACS Symp. Ser. Vol. 593, 1995).
- Solvent removal and/or concentration can be effected by various means known in the art including, but not limited to, reduced pressure evaporation, evaporation, reduced pressure distillation, distillation, and lyophilization.
- the present invention includes the isolation of active ingredients by expanded bed chromatography, moving and simulated moving bed chromatography, and other related methods known in the art (see, for example, G. Sofer, L. Hagel, Handbook of Process Chromatography, Academic Press, 1997 and S. Ahuja, Handbook of Bioseparations, Academic Press, 2000).
- Selective precipitation means includes the use of various solvents and solvent combinations, the use of temperature changes, the addition of precipitant and/or modifiers, and/or modification of the pH by addition of base or acid to effect a selective precipitation of active ingredients or other constituents.
- the invention also includes the isolation of active ingredients by steam distillation, hydrodistillation, or other related methods of distillation known in the art (see, for example, L. M. Harwood, C. J. Moody, Experimental Organic Chemistry, Blackwell Scientific Publications, UK, 1989).
- the present invention further provides for formulations suitable for dermatological applications comprising one or more extract of the invention, one or more active ingredient, or a combination thereof.
- the formulations can optionally comprise other therapeutic or cosmetic agents.
- the formulations are prepared by standard techniques such that they have acceptable toxicity and stability.
- the formulation is to be administered by a route other than topical ⁇ e.g. systemic routes, such as oral, or via intraperitoneal, intravenous, subcutaneous and intramuscular injection)
- the extract and/or active ingredient must demonstrate acceptable hepatotoxicity and must be sufficiently resistant to degradation to allow the site of action to be reached.
- Criteria which must be considered in the preparation of a formulation include, but are not limited to, the physicochemical and biochemical characteristics (bioavailability, toxicity, stability, etc.) of the extracts and/or active ingredients which make up the formulation.
- the formulation is prepared so as to preserve, as much as possible, the maximum inhibitory activity of the active components upon administration, without being harmful to the animal.
- the formulations are prepared by mixing the extract(s) and/or active ingredients together with a physiologically acceptable carrier. Excipients, binders, diluents, and the like can also be included in the formulation.
- the extract(s) and/or active ingredients can be formulated independently if desired and the respective formulations subsequently combined using a diluent or the like and administered, or can be administered independently of each other, either concurrently or at staggered times to the subject.
- the formulations according to the invention may be in solid, semisolid or liquid form and may be adapted for oral (capsules, tablets, phials, troches, and, the like), parenteral, rectal, inhalation, or topical administration, and may be in unit dosage form.
- the formulation may be adapted for slow release in vivo as known in the art.
- the formulations of the invention may be used in conventional form including, but not limited to, solutions, syrups, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, elixirs, injectables, tablets, capsules, suppositories, hydrophobic and hydrophilic creams and lotions.
- parenteral as used herein includes subcutaneous injections, intravenous, intrathecal, intramuscular, intrasternal injection or infusion techniques.
- Suitable carriers include, but are not limited to, hydroxypropyl cellulose, starch (corn, potato, rice, wheat), pregelatineized starch, gelatine, sucrose, acacia, alginic acid, sodium alginate, guar gum, ethyl cellulose, carboxymethylcellulose sodium, carboxymethylcellulose calcium, polyvinylpyrrolidone, methylcellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, polyethylene glycol, powdered cellulose, glucose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, tragacanth, calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, kaolin, mannitol, talc, cellulose acetate phthalate, polyethylene phthalate, shellac, titanium dioxide, carnauba wax, microcrystalline wax, calcium stea
- Formulations intended for oral use may be prepared according to methods known in the art and may contain one or more agents such as sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide elegant and palatable preparations.
- Tablets contain the extract(s) and/or active ingredients in admixture with non-toxic physiologically acceptable excipients that are suitable for the manufacture of tablets.
- excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate: granulating and disintegrating agents for example, corn starch, or alginic acid: binding agents, for example starch, gelatinee or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatinee capsules wherein the extract(s) and/or active ingredients are mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatinee capsules wherein the extract(s) and/or active ingredients are mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- an oil medium for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain extract(s) and/or active ingredients in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example, sodium carboxymethylcellulose, methyl cellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia: dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethyene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example hepta- decaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxy-benzoate, one or more colouring agents, one or more flavouring agents or one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl p-hydroxy-benzoate
- colouring agents for example ethyl, or n-propyl p-hydroxy-benzoate
- flavouring agents for example sucrose or saccharin.
- sweetening agents such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the extract(s) and/or active ingredients in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide palatable oral preparations. These formulations may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the extract(s) and/or active ingredients in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol,
- Formulations of the invention may also be in the form of oil-in-water emulsions.
- the oil phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example, gum acacia or gum tragacanth, naturally- occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate.
- the emulsions may also contain sweetening and flavouring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents.
- the formulations can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension, may be formulated according to methods known in the art using suitable dispersing or wetting agents and suspending agents such as those mentioned above.
- the sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol.
- Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- various bland fixed oils may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- the dermatological formulations are for oral administration.
- Such formulations can be presented as, for example, capsules, cachets, tablets, aerosol sprays, powders, granules, creams, pastes, gels, ointments, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in- water emulsion, or a water-in-oil liquid emulsion.
- compositions contemplated by the present invention include so-called herbal and nutraceutical formulations.
- nutraceutical formulations comprising solid parts of plant(s)
- the plant(s) must be an edible plant.
- the extract(s) and/or active ingredients or plant parts can be used in these herbal remedies and nutraceutical formulations as solutions, purified solutions, or dry powders.
- the dermatological formulations are for topical administration.
- Such formulations may be presented as, for example, aerosol sprays, powders, sticks, granules, creams, liquid creams, pastes, gels, lotions, syrups, ointments, on sponges or cotton applicators, or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
- Topical formulations intended for application to the skin, hair and/or nails can include one or more moisturising agents, i.e. an agent that facilitates hydration of the skin by inhibiting or preventing loss of water from the skin, that absorbs water from the atmosphere and hydrates the skin, and/or that enhances the skin's ability to absorb water directly from the atmosphere.
- moisturising agents generally minimise or prevent the skin from drying and cracking.
- Moisturisers, when used, are typically present in an amount from about 0.01 to 20 weight percent of the formulation.
- Suitable moisturising agents include acidic components, hydrophobic agents, and hydrophilic agents, or combinations thereof.
- moisturising agents that are acidic components include, but are not limited to, 2-hydroxyacetic acid (glycolic acid); 2-hydroxypropanoic acid (lactic acid); 2-methyl 2-hydroxypropanoic acid; 2- hydroxybutanoic acid; phenyl 2-hydroxyacetic acid; phenyl 2-methyl 2-hydroxyacetic acid; 3-phenyl 2-hydroxyacetic acid; 2,3-dihydroxypropanoic acid; 2,3,4- trihydroxybutanoic acid; 2,3,4,5,6-pentahydroxyhexanoic acid; 2-hydroxydodecanoic acid; 2,3,4,5-tetrahydroxypentanoic acid; 2,3,4,5,6,7-hexahydroxyheptanoic acid; diphenyl 2-hydroxyacetic acid; 4-hydroxymandelic acid; 4-chIoromandelic acid; 3- hydroxybutanoic acid; 4-hydroxybutanoic acid; 2-bydroxy
- moisturising agents that are hydrophobic agents include, but are not limited to, ceramide, borage oil (linoleic acid), tocopherol linoleate, dimethicone, glycerinee, and mixtures thereof.
- moisturising agents that are hydrophilic agents include, but are not limited to, hyaluronic acid, sodium peroxylinecarbolic acid (sodium PCA), wheat protein (such as laurdimonium hydroxypropyl hydrolyzed wheat protein), hair keratin amino acids, and mixtures thereof.
- Sodium chloride may also be present, for example, when hair keratin amino acids are included as a moisturiser.
- Other moisturising agents that may be included in the formulations include primrose oil and flax seed oil.
- the formulation may further optionally include one or more of a cysteine component, magnesium component, manganese component, selenium component, and copper component. These components are known in the art to impart beneficial effects to the skin, hair and/or nails.
- a cysteine component may assist in thickening the dermis and supplementing collagen and elastic tissue, which can lead to a reduction of wrinkles and other skin conditions.
- An example of a suitable cysteine component is N-acetyl cysteine, or a pharmaceutically acceptable salt thereof, which can be included in the formulation in an amount from about 1 to 10 weight percent.
- the copper component may contribute to the inhibition elastase activity.
- Various copper compounds, or pharmaceutically acceptable salts thereof, are suitable for inclusion in the formulations.
- copper sebacate can be included in the formulation in an amount from about 5 to 20 weight percent.
- the optional manganese component can be one of a variety of manganese compounds, or pharmaceutically acceptable . salts thereof, for example, manganese ascorbate or a manganese ascorbic acid complex, which can be included in the formulation in an amount from about 0.5 to 10 weight percent.
- Suitable magnesium compounds include magnesium ascorbate or magnesium ascorbic acid complex. The magnesium component can be included in the formulation in an amount from about 1 to 10 weight percent.
- Suitable selenium compounds include selenium complexed with an amino acid, for example, L-selenomethionine. The selenium component can be included in the formulation in an amount from about 0.01 to 3 weight percent.
- the dermatological formulation can also include one or more anti-inflammatory components which facilitate inhibition or suppression of inflammation on or in the skin or in adjacent bodily tissues and thereby helps to reduce redness and swelling of the skin.
- suitable anti-inflammatory components include vitamin E and derivatives thereof, zinc, allantoin, glycyrrhetic acid, azulene, mefenamic acid, phenylbutazone, indometacin, ibuprofen, ketoprofen, ⁇ -aminocaproic acid, hydrocortisone, panthenol and derivatives and salts thereof, zinc oxide and diclofenac sodium.
- the anti-inflammatory component when used, can be incorporated into the formulations of the present invention in an amount between about 0.001 to about 5 weight percent.
- the formulation may also optionally comprise one or more anti-oxidants to help neutralize free radicals and minimise their effect on the skin.
- Anti-oxidants can be enzymatic or non-enzymatic type. Examples include the enzymatic anti-oxidants: superoxide dismutase (SOD), catalase, and glutathione peroxidase, and the non- enzymatic anti-oxidants: Vitamin E (for example, tocopherol) and derivatives thereof, Vitamin A (retinol), Vitamin C (ascorbic acid), carotenoids and derivatives thereof, echinacoside, caffeoyl derivatives, oligomeric proanthocyanidins or proanthanols (such as those obtained from grape seed extract), green tea polyphenols, dibutyl hydroxytoluene, butyl hydroxyanisole, tannin and derivatives thereof such as gallic acid and ellagic acid, flavonoids such as flavone, catechin, quercetin and leucoanthocyanidin
- vitamin C When vitamin C is included in the formulation, it can be in the form of ascorbyl palmitate, dipalmitate L-ascorbate, sodium L-ascorbate-2-sulphate, or an ascorbic salt, such as sodium, potassium, and calcium, or mixtures thereof.
- Vitamin C can be included in the formulations in an amount from about 0.1 to 50 weight percent.
- Vitamin A when included, is usually in the form of vitamin A palmitate.
- Vitamin A can be included in topical formulations in an amount from about 0.5 to 15 weight percent.
- Suitable carotenoids include, for example, beta-carotene, canthaxanthin, zeaxanthin, lycopen, lutein, crocetin, capsanthin, and mixtures thereof. Carotenoids can be included in the formulation in an amount from about 0.1 to 5 weight percent.
- skin benefit ingredients can also be optionally included in the dermatological formulations of the present invention.
- skin benefit ingredients include, but are not limited to, sunscreens and sunblocks, essential fatty acids, retinoids, cell activators, blood-circulation promoters, tanning agents, alpha or beta hydroxy-acids, proteins, peptides and polysaccharides.
- Sunscreens and sunblocks include those materials commonly employed to block ultraviolet light.
- suitable sunscreens and sunblocks include, but are not limited to, titanium dioxide, zinc oxide, talc, red veterinary petrolatum, a cinnamate (such as octyl methoxycinnamate), a benzone (such as oxybenzone or 2-hydroxy-4- methoxy benzophenone), a salicylate (such as homosalicylate or octyl salicylate), a benzoic acid (such as para-aminobenzoic acid), and a benzophenone (such as oxybenzophenone).
- Octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone are commercially available under the trademarks, Parsol MCXTM and Benzophenone-3TM, respectively.
- the exact amount of sunscreen employed in the formulations will vary depending upon the degree of protection desired from the sun's UV radiation and can be readily determined by one skilled in the art.
- Essential fatty acids are those fatty acids which are essential for the plasma membrane formation of all cells. In keratinocytes, EFA deficiency makes cells hyperproliferative. EFAs also enhance lipid biosynthesis in the epidermis and provide lipids used in barrier formation by the epidermis.
- essential fatty acids include linoleic acid, ⁇ -olinolenic acid, homo- ⁇ -linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidom ' c acid, ⁇ -linolenic acid, timnodonic acid, hexaenoic acid and mixtures thereof.
- Azoles such as climbazole, bifonazole, clotrimazole, ketoconazole, miconazole, econazole, itraconazole, fluconazole, terconazole, butoconazole, sulconazole, lionazole and mixtures thereof, may also optionally be included in the formulations.
- Cell activators include, for example, royal jelly, photosensitizers, cholesterol and derivatives thereof, fetal calf blood extract, vitamin A, retinols and retinoids, citric acid, lactic acid, tartaric acid, malic acid, glycolic acid, succinic acid, serine, glutamic acid, hydroxyproline, theanine, pyrrolidone carboxylic acid, yeast extract, Lactobacillus extract and Bifidobacterium bifidum extract.
- the cell activator(s) can be incorporated into the formulations in an amount between about 0.001 and 5 weight percent.
- blood circulation promoters are cephafanthine, tocopherol and derivatives thereof, nicotinic acid and derivatives thereof, nonanoic acid vanillylamide, capsaicine, zingerone, cantharides tincture, ichthammol, caffeine, tannic acid, ⁇ -borneol, cyclandelate, cinnarizine, tolazoline, acetylcholine, verapamil, ⁇ -oryzanol, camphor, hinokitiol, and enzymes such as lipases and papain.
- the blood circulation promoter(s) can be incorporated into the formulations in an amount between about 0.01 to 20 weight percent.
- the formulations of the present invention can further optionally comprise one or more thickener.
- a thickener will usually be present in amounts from 0.1 to 20% by weight of the formulation.
- Exemplary thickeners are cross-linked polyacrylate materials available under the trademark CarbopolTM (B. F. Goodrich Company), xanthan gum, carrageenan, gelatinee, karaya, pectin and locust bean gum.
- the thickening function may be accomplished by a moisturiser component of the formulation.
- silicone gums and esters such as glycerol stearate have dual functionality.
- adjunct minor components can also optionally be incorporated into the dermatological formulations, for example, colouring agents, opacifiers, perfumes and preservatives (for example, imidazolidinyl urea, dimethyl imidazolidinone or diazolidinyl urea). Amounts of these materials can range from 0.001% up to 20% by weight of the formulation.
- the dermatological formulations intended for topical application can be packaged in a suitable container to suit the viscosity and intended use.
- a lotion or fluid cream can be packaged in a bottle or a roll-ball applicator, a capsule, a propellant- driven aerosol device or a container fitted with a pump suitable for finger operation.
- the composition is a cream or paste, it can simply be stored in a non- deformable bottle or squeeze container, such as a tube or a lidded jar.
- the plant extracts of the invention and/or active ingredients derived from the extracts, and formulations comprising the extracts and/or active ingredients are suitable for use for the routine care of the skin, hair and/or nails, to improve the health and/or appearance of the skin, hair and/or nails and in the treatment or prevention of a variety of dermatological conditions.
- a dermatological condition is a condition present on one or more of the components of the integumentary system of a subject, such as the skin, hair or nails, that is caused by ageing or by intrinsic or extrinsic factors.
- Intrinsic factors include, for example, the genetic make up of an individual as well as pathological conditions that cause undesirable effects on the skin, hair or nails.
- Extrinsic factors include, but are not limited to, sunlight, radiation, air pollution, wind, cold, dampness, heat, chemicals, smoke, and smoking.
- an effective amount of one or more plant extracts and/or active ingredients of the invention, or a dermatological formulation comprising an effective amount of one or more plant extracts and/or active ingredients can be administered to a mammal as part of routine skin/hair/nail maintenance, in order to improve the health and/or appearance of the skin, hair and/or nails or in order to treat or prevent a dermatological condition.
- the plant extracts, active ingredients or formulations are administered topically to a mammal.
- Examples of dermatological conditions contemplated by the present invention include, but are not limited to, dry skin; dandruff; acne; keratosis; psoriasis; eczema; pruritus; age spots; reduced skin moisture; spider veins; senile purpura; lentigines; melasmas; deepening of skin lines; blotches; wrinkles; blemished skin; nodules; atrophy; rosacea; impetigo; elastotic changes characterized by leathery, course, rough, dry and yellowish skin; telangiecatic skin; hyperpigmented skin; hyperkeratotic skin; inflammatory dermatoses; "bullous" diseases, such as epidermolysis bullosa; hair breakage; hair loss; weathering damage; thinning of the hair; brittle nails; thinning nails; flaking nails and ridged nails.
- Improving the health and/or appearance of the skin, hair and nails includes, for example, eliminating or preventing the dark skin, melasma or ephelis generated or formed due to a variety of causes such as exposure to ultraviolet rays, changes in the hormone balance and genetic programs; lightening the dullness of the skin; improving the gloss and/or firmness of the skin; inhibiting or preventing the progress of the skin- ageing phenomenon; reducing minor blemishes; controlling dandruff; reducing redness or inflammation of the scalp, and the like.
- the dermatological formulations of the presentinvention can also be used to promote wound healing and/or decrease the risk of scarring.
- an effective amount one or more plant extracts and/or active ingredients of the invention, or a dermatological formulation comprising an effective amount of one or more plant extracts and/or active ingredients is administered to a mammal in order to attenuate one or more undesirable structural changes in the skin, such as wrinkling and/or sagging of the skin, loss of skin elasticity, redness, inflammation, formation of lesions, thinning of the epithelium, abnormal migration of cells within the skin (such as that which occurs during angiogenesis or inflammation), or various combinations thereof.
- One embodiment of the present invention provides for the use of an effective amount of one or more plant extracts and/or active ingredients of the invention, or a dermatological formulation comprising an effective amount of one or more plant extracts and/or active ingredients as a skin care product.
- a skin care product refers to a product intended for use in the maintenance and optimization of skin health and preservation, from the standpoint of appearance and function.
- the skin care product is an anti-ageing product.
- An anti-ageing product is a product intended to use in attenuating or preventing skin ageing due to intrinsic or extrinsic factors.
- Skin ageing phenomena include, for example, skin thinning, fine and coarse skin wrinkling, sagging, loss of elasticity, and the like. Accordingly, the present invention provides for the administration of an effective amount one or more plant extracts and/or active ingredients of the invention, or a dermatological formulation comprising an effective amount of one or more plant extracts and/or active ingredients to a mammal in order to produce an anti-ageing effect.
- an effective amount it is meant an amount of the plant extract or active ingredient that provides a beneficial effect in the treatment of a dermatological condition or a desired skin improvement effect. It should be understood by one of ordinary skill in the art that this amount will vary depending on the application and on the individual subject and will be readily determinable by one of skill in the art.
- Appropriate doses of a formulation comprising the plant extract(s) and/or active ingredient will also vary according to the age, body weight, and response of the individual patient. In general, the total daily dose range, is from about 0.01 mg to about 2,000 mg of the plant extract(s) and/or active ingredient administered in about one to ten doses or applications.
- the present invention contemplates the large-scale preparation of the plant extracts of the invention.
- the extracts can be prepared on a commercial scale using the extraction process employed in the analytical scaie preparation the extract of interest.
- One embodiment of this aspect of the invention is presented in Figure 3.
- the small-scale extraction procedure is simply scaled-up and additional steps of quality control are included to ensure reproducible results.
- the process outlined in Figure 5 can be adapted for scale-up for commercial purposes.
- modifications to the small-scale procedure that may be required during scale-up for industrial level production of the extract.
- modifications include, for example, alterations to the solvent being used or to the extraction procedure employed in order to compensate for variations that occur during scale-up and render the overall procedure more amenable to. industrial scale production, or more cost effective. Modifications of this type are standard in the industry and would be readily apparent to those skilled in the art.
- the present invention further provides for a rapid method for screening plant extracts to identify those capable of inhibiting one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE, which are suitable for incorporation into the dermatological formulations of the invention.
- the process comprises the following general steps: (a) generating a plurality of extracts from plant material by solvent extraction; (d) analysing the ability of each plant extract to inhibit one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE; and selecting those extracts that are capable of inhibiting the activity of at least one of the listed EPs.
- the extracts exhibiting inhibitory activity can then be screened for their ability to affect one or more cellular activities in skin cells, such as attenuating the breakdown of a structural component of the ECM ⁇ i.e.
- the plurality of extracts in step (a) above can be generated from plant material from a single plant source using different solvents or the plurality of extracts can be generated by first selecting a group of plants of interest, harvesting plant material from each plant in the group, then extracting the plant material with a solvent or solvents to generate a plurality of extracts.
- the extracts to be screened are prepared from plant material derived from a plant or plants of interest, i.e. "potential plants.”
- Potential plants include all species of the Kingdom Plantae, including terrestrial, aquatic or other plants that can be subjected to the methodology described herein in order to generate an extract that can be tested for its ability to inhibited at least one of the above-listed skin EPs.
- Examples of potential plants include, but are not limited to, those belonging to the following classifications: Superdivisionspermatophyta - Seed plants; Division Coniferophyta - Conifers; Class Pinopsida, Order Pinales; Family Araucariaceae - Araucaria family; Family Cephalotaxaceae - Plum Yew family; Family Cupressaceae - Cypress family; Family Pinaceae - Pine family; Family Podocarpaceae - Podocarpus family; Family Taxodiaceae - Redwood family; Order Taxales, Family Taxaceae - Yew family; Division Cycadophyta - Cycads, Class Cycadopsida, Order Cycadales, Family Cycadaceae - Cycad family; Family Zamiaceae - Sago-palm family; Division Ginkgophyta - Ginkgo, Class Ginkgoopsida, Order Ginkgoales, Family Ginkgoaceae - Ginkgo family; Division Gnet
- Calamus family Family Araceae - Arum famiry,Family Lemnaceae - Duckweed family; Order Arecales, Family Arecaceae - Palm family; Order Cyclanthales, Family
- Spiderwort family Family Mayacaceae - Mayaca family, Family Xyridaceae -
- potential plants comprise: Abelmoschus esculentus, Abies balsamea, Abies cephalonica, Abies firma, Abies lasiocarpa, Acer campestre, Acer mandshurica, Acer palmaturn "burgundy,” Acer tataricum, Acer truncatum, Achillea millefolium, Achillea ptarmica, Achillea tomentosa, Acolypha hispida, Aconitum napellus, Aconitum spp., Acorus calamus, Actaea racemosa, Actinidi colonicta, Actinidia arguta, Actinidia chinensis, Actinidia colomicta, Adansonia digitata, Adianthum radiatum, Adianthum trapezieformis, Adiantum pedatum, Adiantum tenerum, Aechmea luddemoniana, Aesculus hypocastanum, A
- Cichorium intybus Cinnamomum verum, Cirsium arvense, Cissus discolor, Cistus incanus, Citinis coggriaria, Citrullus colocynthis, Citrullus lanatus, Citrus limettoides, Citrus limon, Citrus reticulata, Citrus sinensis, Citrus x paradisi, Clematis alpina, Clematis armandii, Clematis chiisanensis, Clematis rectae, Clerodendrurn speciossicum, Cobiaeum varilarturn, Coccoloba caracasana, Cocculus laurifolius, Cocos nucifera, Coix lacryma-jobi, Colocasia spp., Comus mass, Convalaria majalis, Conyza canadensis, Corchorus olitorius, Coreopsis verticillata, Coriandrum sativum, Cornus alba
- balsamita Tanacetum cinerariifolium, Tanacetum partheniurn, Tanacetum vulgare, Tapeinochilos spectabilis, Taraxacum officinale, Taraxacum officinalis, Taxodium dixticum, Taxus cuspidata, Taxus hiksii, Taxus media, Taxus x media, Tetraclinis articulata hinensis, Tetradenia riparia, Teucrium chamaedrys, Thalictrum aquilegiifolium, Thalictum flavum, Thlaspi arvense, Thuja occidentalis, Thymus camosus, Thymus cretaceus, Thymus cytridorus "aureus, Thymus fragantissimus, Thymus herba-barona,Thymus lemabarona, Thymus portugalense, Thymus praecox, Thymus praecox subsp.
- Thymus pseudolamginosus Thymus pseudolanuginosus
- Thymus puleglodes "lemons”
- Thymus puliglodes Thymus serphylum
- Thymus speciosa Thymus thrasicus
- Thymus vulgaris Thymus vulgaris "argenteus”
- Thymus vulgaris oregan ⁇
- Thymus wooly Thymus x citriodorus
- Tiarella cordifolia Tiarella spp., Tragopogon porrifolius, Tragopogon spp., Trambe pontica, Trevesia sungaica, Trichosanthes kirilowii, Trifolium hybridum, Trifolium incarnatum, Trif ⁇ lium pannonicum, Trifolium pratense, Trifolium repens, Trigonella foenum-graecum, Triticum aestivum, Triticum aestivum subsp.
- Groups of potential plants may also be selected based on their indigenous geographical regions.
- one group of potential plants could comprise plants that are indigenous to arid regions, for example, those located between 35° north latitude and 35° south latitude.
- potential plants comprise: the agave, Agavaceae, family including such members as: Yucca elata, Y. breviflora, Agave deserti, A. chrysantha, Dasylirion wheeleri; the buckwheat, Polygonaceae, family, such as Eriogonum fasciculatum; the crowfoot, Ranunculaceae, family, such as Delphinium scaposum, Anemone tuberosa and D.
- microphyllum Lotus huminstratus, Krameria parvifolia, Parkinsonia aculeata, Calliendia eriophylla, Lupinus arizonicus, Olyneya tesota, Astragalus lentiginosus, Psorothamunus spinosus and Lupinus sparsiflorus; members of the loasa family, Loasaceae, including Mentzelia involucrata, M. pumila and Mohavea Confertiflora; members of the cactus, Cactaceae, family, such as Carnegiea gigantia, Opuntia leptocaulis, Ferocactus wislizenii, O. bigelovii, O.
- members of the milkweed Asclepiadaceae, family, including Asclepias erosa, A. sublata and Sarcostemma cynanchoides
- members of the borage Boraginaceae, family, such as Cryptantha augusti folia and Amsinckia intermedia
- members of the sunflower Compositae, family, including Baccharis sarothroides, Monoptiilon belloides, Erieron divergens, Zinnia acerosa, Melampodium leucanthan, Chaenactis fremontii, Calycoseris wrightii, Malacothrix californica, Helianthus annus, H.
- members of the phlox Polemoniaceae, family, such as Luanthus aureus
- members of the unicorn plant Martyniaceae, family, such as Proboscidiea altheaefolia
- members of the gourd Cucurbitaceae, family, such as Cucurbita digitata
- members of the lily Lilaceae, family, including Calochortus kennedyi, Dichelostemma pulchellum, Allium macropetalum and Hesperocallis indulata
- members of the ocotillo Fouquieriaceae, family, including Fouquieria splendens
- members of the figwort Scrophulariaceae, family, such as Castilleja sp., Penstemon parryi and Orthocarpus purpurascens
- members of the acanthus Acanthaceae, family, including Anisacanthus thurber
- members of the bignonia, Bignoniaceae, family such as Chilopsis linearis
- members of the vervain, Verbenaceae, family including Glandularia gooddugii and Verbena neomexicana
- members of the mint, Labiatae, family such as Hyptis emoryi and Salvia columbariae
- members of the broomrape, Orobanchaceae, family such as 2004/002007
- Orobanche cooperi members of the portulaca, Portulaceae, family, such as Talinum auriantiacum; members of the carpet- weed, Aizoaceae, family, such as Sesuvium verrucosum; members of the flax, Linaceae, family, such as Linum lewisii; members of the potato, Solanaceae, family, including Nicotiana trigonophylla and Physalis lobata; and members of the cochlospermum, Cochlospermaceae, family, such as Amoreuxia palmatifida.
- the potential plant(s) can be subjected to a harvest stress treatment.
- a stress treatment comprises contacting or treating the potential plant(s), or material from the potential plant(s), with one or more stressor.
- the stressor can be a chemical compound or a physical treatment. Examples of suitable stressors are provided above. Various combinations of stressors and treatment regimes can also be employed as would be apparent to one skilled in the art.
- the plant material may be used immediately after harvest, or it can be stored for a period of time prior to performing the extraction procedure(s). If desired, the plant material can be treated prior to storage, for example, by drying, freezing, lyophilising, or some combination thereof. Following treatment to prepare the plant material for storage, the plant material may be stored for a period of time prior to preparation of the extract.
- the storage time may be of various duration, for example, the storage period may be between a few days and a few years.
- the plant material is stored for a period of less than one week.
- the plant material is stored for a period between one week to one month.
- the plant material is stored for a period of between one month to six months.
- the plant material is stored for periods of between four months to one year and for a period over one year in duration.
- the plant material is subjected to an extraction process as depicted in Figure 5.
- the plant material is- subjected to two separate extraction processes concurrently resulting in two separate potential extract As.
- the procedure for each extraction process entails contacting the solid plant material with a solvent with adequate mixing and for a period of time sufficient to ensure adequate exposure of the solid plant material to the solvent such that inhibitory activity present in the plant material can be taken up by the solvent.
- the extraction procedures are conducted over a period of time between about 10 minutes and about 24 hours at a temperature between about 4 0 C and about 5O 0 C. Other times and temperatures may be employed in the extraction process as described above. Adequate contact of the solvent with the plant material can be encouraged by shaking the suspension.
- the liquid fraction is then separated from the solid (insoluble) matter resulting in the generation of two fractions: a liquid fraction, which is a potential extract, and a solid fraction. Separation of the liquid and solid fractions can be achieved by one or more standard processes known to those skilled in the art.
- Solvents A, B and C in Figure 1 generally represent separate classes of solvents, for example, aqueous, alcoholic and organic.
- the solvents can be applied in specific order, for example, a polar to non- polar order or in a non-polar to polar order. Alternatively, the solvents can be applied in a random sequence. In all cases, however, the solid matter should be dried prior to contact with the subsequent solvent.
- the plant material employed in the extraction process can be the entire potential plant, or it can be one or more distinct tissues from a plant, for example, leaves, seeds, roots, stems, flowers, and the like, or various combinations thereof.
- the plant material can be fresh, dried or frozen. If desired, the plant material can be treated prior to the extraction process in order to facilitate the extraction process. Typically such treatment results in the plant material being fragmented by some means such that a greater surface area is presented to the solvent. For example, the plant material can be crushed or sliced mechanically, using a grinder or other device to fragment the plant parts into small pieces or particles, or the plant material can be frozen liquid nitrogen and then crushed or fragmented into smaller pieces.
- the solvent used for each extraction process can be aqueous, alcoholic or organic, or a combination thereof.
- plant material is extracted with an aqueous solvent.
- an aqueous solvent comprising an aqueous buffer at pH 6 — 8 for a period of between 30 minutes to 8 hours at a temperature between about 4 to about 5O 0 C is used for the extraction.
- plant material is extracted with an alcoholic solvent, such as ethanol, methanol, 1-propanol, 1-butanol, 2-propanol, 2- butanol, 2-methyl- 1-propanol, 2-methyl-2-propanol, glycerine, ethylene glycol, propylene glycol, diethylene glycol, dipropylene glycol or 1,3-butylene glycol or a combination of alcoholic solvents.
- a combination of ethanol and methanol is used as the alcoholic solvent, wherein the range of ethanohmethanol is between about 50:50 and about 85:15.
- a glycol is used as the alcoholic solvent.
- the plant material is contacted with an alcoholic solvent for a time period between about 10 minutes to one hour at a temperature between about 4 to about 25 0 C.
- plant material is extracted with an alcoholic solvent in combination with a co-solvent, which may be aqueous or organic.
- a co-solvent which may be aqueous or organic.
- a combination of ethanol and water is used as the solvent, wherein the range of ethanol:water is between about 50:50 and about 85:15.
- a combination of a glycol and water is used as the solvent, wherein the range of glycol:water is between about 95:5 and about 50:50.
- plant material is extracted with an organic solvent, such as diethylether, hexane, heptane, dichloromethane, or ethylacetate.
- organic solvent such as diethylether, hexane, heptane, dichloromethane, or ethylacetate.
- dichloromethane is used as the solvent and the plant material is shaken for one to twenty-four hours with the solvent.
- the potential extracts can be tested directly (after being dissolved or dispersed in a suitable solvent) for their ability to inhibit skin EP activity, or they may be subjected to further procedures as described below and outlined in Figures 2 and 6.
- the potential extracts can be subjected to procedures to remove fatty acids or chlorophyll components that may interfere with the protease activity or other assays.
- procedures known in the art may be employed.
- one or more additional partitioning step using an organic solvent, such as hexane, heptane or ethyl acetate, is included.
- the liquid potential extract can be concentrated and solubilised in an appropriate solvent prior to the one or more partitioning step, if desired.
- the present invention contemplates that the extraction process may be carried out on various scales including known large, medium and small-scale methods of preparing extracts.
- the potential extracts are tested for their ability to inhibit one or more skin EPs selected from the group of: MMP-I, MMP-2, MMP-3, MMP-9 and HLE, using one of a variety of techniques known in the art including, but not limited to, those described herein.
- Those plant extracts that decrease the activity of at least one skin EP by at least 20% are selected for further testing.
- plant extracts that inhibit the activity of one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE by at least 30% are selected.
- plant extracts that inhibit the activity of one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE by at least 40% are selected.
- plant extracts that inhibit the activity of one or more of MMP-I, MMP- 2, MMP-3, MMP-9 and HLE by at least 50% are selected.
- the extracts can be tested against an individual skin EP or against, a panel comprising two or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE.
- the extracts can be tested individually or a plurality of extracts can be tested simultaneously using high- throughput assays, as known in the art. Simultaneous testing of a plurality of extracts maximises the number of extracts that can be tested in a set period of time and thus decreases the overall time for the screening process.
- Those extracts identified as being capable of inhibiting one or more of MMP-I, MMP-2, MMP-3, MMP-9 and HLE are subsequently screened for their ability to affect one or more cellular activities in skin cells.
- Such cellular activities include, for example, attenuating the breakdown of a structural component of the ECM ⁇ i.e. collagen, fibronectin, fibrillin and/or elastin); attenuating endothelial cell migration; increasing collagen production; attenuating UV-induced extracellular protease activity and/or attenuating tractional forces generated by fibroblasts.
- the extracts can be tested using standard methods such as those described above.
- extracts identified by the above process may be submitted to other standard tests, such as cytotoxicity tests, stability tests, bioavailability tests and the like, to determine their suitability for inclusion in a dermatological formulation of the invention. Exemplary tests are described above.
- Optional Pre-Harvest Treatment Aerial parts of a living plant were sprayed with an aqueous solution of gamma linolenic acid (6,9,12-Octadecatrienoic acid, Sigma L- 2378) (stress G) or arachidonic acid (5,8,11,14-Eicosatetraenoic acid, Sigma A-3925) (stress A) (400 ⁇ M in water with 0.125% (v/v) Triton X-100) to completely cover the leaves. Twenty to twenty-four hours after the stress, plants were harvested.
- gamma linolenic acid (6,9,12-Octadecatrienoic acid, Sigma L- 2378)
- arachidonic acid (5,8,11,14-Eicosatetraenoic acid, Sigma A-3925)
- stress A 400 ⁇ M in water with 0.125% (v/v) Triton X-100
- Harvest Solid Sl and Optional Storage Treatment More than 4 grams of leaves, stems, fruit, flowers, seeds or other plant parts were harvested from stressed or non- stressed plants and frozen immediately in dry ice, then transferred as soon as possible to a -20 0 C freezer until use. Plant materials may be stored at -2O 0 C for than a year without losing inhibitory activity. Temperature was monitored to ensure a constant condition.
- Extraction Process I Aqueous Extraction: To each 4.5 grams of plant powder, 12 ml of a cold solution of 100 mM Tris, pH 7.0 was added. The mixture was thoroughly vortexed for 2 minutes. The mixture was kept on ice for 30 minutes and vortexed after each 10 minute period of time. The sample was centrifuged in a CorexTM 30 ml tube for 5 minutes at 4500 rpm. The resulting supernatant was decanted in a 15 ml tube after filtration with a MiraclothTM filter. This extract represents Potential Extract A in Figure 1. The pellet, referred to as Solid S2, was kept for ethanolic extraction.
- the aqueous extract (Potential Extract A) was further purified in order to determine its EP inhibition capability.
- the Potential Extract A was purified by size-exclusion chromatography, wherein the aqueous extract was chromatographed on a calibrated Sephadex G-25 column (1 x 10 cm) using a 20 mM Tris-HCl, 150 mM NaCl, pH 7.5 buffer as eluant. Fractions corresponding to compounds that appeared to have a molecular weight (MW) less than 1500 daltons (D) were pooled to constitute the purified aqueous extract.
- MW molecular weight
- the extract Prior to analysis of the aqueous extract for inhibitory activity as described in Example II, the extract was treated with 10% gelatine-Sepharose (Pharmacia Biotech, Uppsala, Sw.) in order to remove unspecific enzyme ligands.
- 10% gelatine-Sepharose Pharmacia Biotech, Uppsala, Sw.
- To ImL of extract lOO ⁇ L of gelatine-Sepharose resin was added in a microassay tube, the solution in the tube was mixed, kept on ice for 30 minutes, and then centrifuged 5 minutes at 5,000 rpm. The supernatant was removed and used directly for assays.
- the ethanolic extract, Potential Extract B was purified by liquid/liquid extraction prior to analysis by enzymatic assay.
- 1 ml of ethanolic extract was evaporated under vacuum, dissolved in 150 ⁇ l of dimethylsulfoxide (DMSO), and completed to a final volume of 1.5 ml with Tris buffer (final concentration: Tris-HCl 20 mM; pH 7.5).
- Tris buffer final concentration: Tris-HCl 20 mM; pH 7.5.
- Tris buffer final concentration: Tris-HCl 20 mM; pH 7.5
- Tris buffer final concentration: Tris-HCl 20 mM; pH 7.5
- the aqueous phase was removed and treated with 10% gelatine-Sepharose (Pharmacia Biotech, Uppsala, Sw) to remove non-specific enzyme ligands prior to conducting subsequent assays.
- 10% gelatine-Sepharose Pharmacia Biotech, Uppsala, Sw
- To 1 ml of extract lOO ⁇ L of gelatine-Sepharose resin was added in a microassay tube, the tube was mixed, kept on ice for 30 minutes, and then centrifuged 5 minutes at 5,000 rpm. Supernatant was removed and used directly for assays as described in Example ⁇ .
- Extraction Process III - Organic Extraction To the pellet, Solid S3, collected from the previous ethanolic extraction, 12 ml of cold dichloromethane was added and the mixture was thoroughly vortexed for 2 minutes.
- the organic extract was diluted 1:10 in a solution of DMSO:Methanol:Tris (2OmM, pH 7.5) (10 :50 :40) (Solution A), i.e., 220 ⁇ l of extract was added to 2.0 ml of solution A. After 10 seconds of vigorous vortex, the mix was sonicated for 10 seconds. Dissolved extracts were subsequently applied to a solid phase extraction plate (Discovery SPE-96, Sigma Chemical Co, St-Louis, Mo). After initial conditioning of the columns with 1 ml of methanol, columns were equilibrated with solution A, and extract samples were deposited on the columns. Eluti ⁇ n was completed with solution A (final volume of 2 ml) and this fraction was used directly in assays as described in Example II.
- Solution A i.e., 220 ⁇ l of extract was added to 2.0 ml of solution A. After 10 seconds of vigorous vortex, the mix was sonicated for 10 seconds. Dissolved extracts were subsequently applied
- the inhibitory activity of sample compositions towards human MMP-I, human MMP-2, human MMP-3, human MMP-9 and/or human leukocyte elastase (HLE) were determined using either fluorogenic substrates or the FASC assay.
- MMP-I, -2, -9 were purified from natural sources (human immortalized cell lines: 8505C (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) for MMP-I, HT-1080 (ATCC 5 Manassas, VA) for MMP-2 and THP-I (ATCC, Manassas, VA) for MMP-9) as described in literature and based on protocols found in LM. Clark: «Matrix metalloproteinases protocols ⁇ , Humana Press (2001). Recombinant human MMP-3 was overexpressed in E. coli and purified according to Windsor LJ, Steele DL (2001), Methods MoI Biol 151:191-205.
- Human leukocyte elastase was obtained from Calbiochem (San Diego, CA). Human MMP-9 was purified as previously described. The assay was based on the method described in Canadian Patent No. 2,189,486 (1996) and by St-Pierre et al, ⁇ Cytometry
- HLE activity with afluorogenic proteic substrate HLE was obtained from Calbiochem (San Diego, CA). The activity of HLE was measured by an assay based on the increase of fluorescence of a proteic substrate (beta-casein) heavily labelled with Alexa-488 dye (Molecular Probes, Eugene, Or). The substrate, when highly labelled with the dye, will almost quench the dye fluorescence. Cleavage of the substrate will result in an increase of the fluorescence which can be measured with a spectrofluorometer, and which was proportional to protease activity.
- a proteic substrate beta-casein
- Alexa-488 dye Molecular Probes, Eugene, Or
- aqueous extracts prepared as described in Example I were preincubated with 1:10 of gelatine-Sepharose 4BTM for 30 minutes to remove fluorescence quenching.
- ethanolic extract an initial hexane extraction was performed and samples were treated with 1:10 of gelatine : Sepharose 4BTM to remove quenching.
- aqueous, ethanolic or organic extract to be tested 10 ⁇ l of purified enzyme at concentrations previously mentioned for the enzymatic assay, 5 ⁇ l of dissolved fluorogenic peptide or 10 ⁇ l of dissolved fluorescent proteic substrate (final concentration of 10 ⁇ M) and 40 ⁇ L of the aqueous, ethanolic or organic extract to be tested were mixed in a final volume of 75 ⁇ l (completed with TNCZ for fluorogenic peptide substrate assay or 2OmM citrate pH 3.3 buffer for fluorescent protein substrate assay). All assays were performed in 96 well plate and the reaction was started by the addition of substrate.
- the FASC assay 35 ⁇ l of the treated extract prepared as described in Example I, 5 ⁇ l of the purified enzyme prepared as described previously, 5 ⁇ l of concentrated buffer solution (TNCZ), and 5 ⁇ l of gelatine-FITC beads were typically used.
- the initial step of the assay was the incubation of the reaction without beads for a 30 minutes period on ice to allow the binding of inhibitors to enzyme. Fluorescent beads were added and the reaction mix was incubated for 90 minutes at 37 0 C. The reaction was stopped by transfer of the mix in 0.5 ml of 20 mM Tris, 150 mM NaCl; pH 9.5 buffer. This tube was analyzed in the flow cytometer (Epics MCL, Beckman Coulter, Mississauga, Ontario) as described in Canadian Patent Application No. 2,189,486 (1996).
- E A is the protease activity in the absence of the plant extract and E B is the protease activity in the presence of the extract.
- Extracts were separated by HPLC on an Agilent 1100 system (San Fernando, CA).
- Fractions of interest (demonstrating a biological activity) were then re-isolated at a larger scale for further analysis and characterisation.
- Method B is summarized in general terms in Figure 5.
- the method can be divided into two main parts corresponding to preliminary analytical scale extraction and a second larger scale extraction process.
- the processed plant materials (leaves, roots, seeds and the like) were obtained by dedicated greenhouse cultivation (with or without physical / chemical stress), from commercial suppliers, or by gathering from non-cultivated natural sources. For each plant used in either analytical scale or large scale extraction, a properly identified and labelled sample was kept in storage in the laboratory.
- the collected dried plant material (2 - 10 g) was first submitted to solid-liquid extractions to generate crude extract A (mg scale). Two different solvents were tested (ethanol/methanol or ethanol/water mixtures). The extracts were then defatted with hexane to yield hydroalcoholic or alcoholic extract B and hexane extract C. A partitioning of extract B with ethyl acetate was then performed after dilution with water to yield aqueous extract E and organic extract F.
- the extracts were sampled and evaluated for their ability to inhibit one or more target protease and for their ability to affect one or more cellular activity in the skin using the methods described below.
- the selection includes a decision regarding part of the plant and quantity of dried material needed to obtain sufficient mass of extract for pure active compound isolation.
- the selection also involves a choice of solvent system (aqueous versus alcoholic) and active extract (B, E or F) to be used in further work.
- the extracts were also analyzed by Thin Layer Chromatography (TLC) with different reagents specific to classical chemical groups of natural products (terpenes, alkaloids, phenolic acids, polyphenols) to evaluate the increase in concentration achieved by partitioning at each step, and also to remove any materials likely to produce false positive results (fatty acids, chlorophylls) and to provide an indication of which fractionation steps to use in further extractions.
- TLC Thin Layer Chromatography
- a repeat analytical scale extraction is performed to confirm the biological activity before beginning the large-scale extraction process.
- the first step is to release the secondary metabolites from the dried and powdered material by means of an all purpose solvent mixture which is selected based on the results obtained in the analytical scale preparation. This can be done by successive maceration / percolation operations using the same solvent which should dissolve most natural compounds at the same time.
- the bulk of the inert and insoluble material such as cellulose is then removed by filtration. Conditions of drying and grinding are controlled (temperature of drying less than 45°C, particles size).
- the second step is to remove a portion of the unwanted material in a series of liquid- liquid low resolution extractions using solvents of different polarity with the aim of a multi-gram mixture containing all the natural products of interest and to remove the most of the undesired material.
- the extraction protocol is illustrated in Figure 6 and is essentially the same as the procedure for the analytical preparation.
- the dried and pulverized material (2-3 Kg for large scale) is extracted repeatedly (maceration / percolation) with ethanol / methanol [85:15] v/v (a) or ethanol / water [85:15] v/v (b) mixtures (3 x 5 - 10 L) at room temperature for 2 x 24-48 h, based on the analytical scale results (yield of extraction).
- the combined alcoholic extracts (A) are concentrated under reduced pressure, diluted with water (10 -15%) and extracted with hexane (or heptane) to yield hexane extract (C) and hydroalcoholic fraction (B). This is then concentrated and diluted with ethanol (20%) before being extracted with ethyl acetate to yield aqueous (E) and ethyl acetate extracts (F).
- EXAMPLE V Protease Inhibition by Plant Extracts in a Human Skin Model
- a cellular model of the skin was used to determine the potential inhibitory effect of aqueous and ethanolic plant extracts prepared as described in Example I in the skin.
- Human dermal fibroblasts (Cascade Biologies, 5 x 10 4 /well) 5 type 1 collagen (3 mg/ml, Sigma), and cell culture medium were pipetted into 12 or 24-well untreated Falcon plates and incubated for 1 hour at 37 0 C, allowing for gel formation. Cell culture medium was then added to the wells and the gels were incubated overnight at 37 0 C in a 5% CO 2 controlled atmosphere. The gels were incubated for 5 days, with media changes at days 2 and 4, allowing for fibroblast proliferation, with collagen and protease synthesis and secretion into the gel.
- B Buds; E: Ears; Fl: Flower; Fr: Fruit; L: Leaf; R: Root; S: Seed; St: Stem
- I X dose at which an inhibition of 50% was obtained in initial screening.
- Aqueous and alcoholic plant extracts that inhibit MMP-9, MMP-2 or MMP-I were prepared as described in Example I and underwent further testing to ascertain that they contain stable, non-cytotoxic molecules that are appropriate for product development. Stability is ascertained by recovery of protease inhibition over time under various conditions, including physiological conditions. Cytotoxicity is ascertained by incubation of the extracts with various cell types, including those indicated below.
- IX Concentrations of plant extracts are expressed as a function of the IC 5O concentration determined for protease inhibition, which is termed IX.
- the extracts are, therefore, capable of decreasing the activity of at least one extracellular protease by at least 50% when measured according to one of the assays described herein.
- the IX concentration can vary depending on the plant and the solvent used in the preparation of the extract.
- the average concentration of a IX aqueous extract is about 1.6 mg/ml, whereas the average concentration of a IX alcoholic extract is about 4 mg/ml.
- 4 different concentrations were used (0.3 IX, 0.62X, 1.25X and 2.5X) in duplicate.
- EGM-2 (700 ⁇ l) was added to the bottom chamber as a chemo-attractant.
- HUVECs 100 ⁇ l of 10 6 cells/ml
- buffer containing the plant extract at the appropriate dilution were added to the upper chamber (duplicate wells of each plant extract at each dilution).
- the membrane was rinsed with PBS, fixed and stained. The cells on the upper side of the membrane were wiped off, three randomly selected fields were counted on the bottom side.
- the percent inhibition of migration is calculated as follows:
- A is the average number of cells per field in the control well and B is the average number of cells per field in the treated wells.
- HUVECs were prepared as suspensions of 2.5 x 10 5 cells per ml in EGM-2, then 500 ⁇ l of HUVECs preparation was mixed with 500 ⁇ l of 2X of the desired dilution of plant extract or control drug and 200 ⁇ l were added to each well. Four dilutions of each extract were tested in duplicate. After 18-24 hours at 37 0 C in 5% CO 2 , the cells had migrated and organized into cords (see Figure 4, which shows the results using an extract from Rheum rhabarbaram).
- A is the average number of cell junctions per field in the control well and B is the average number of cell junctions per field in the treated wells.
- B Buds; FI: Flower; Fr: Fruit; L: Leaf; P: Pods; R: Root; S: Seed; St: Stem
- I X dose at which an inhibition of 50% was obtained in initial screening.
- EXAMPLE VTI Plant Extracts that Inhibit Human Leukocyte Elastase (HLE)
- Plant extracts were prepared as described in Example I and were tested for their ability to inhibit HLE as described in Example II.
- the solvents used in this Example were: butylene glycol (100%), butylene glycol/water (50/50, v/v), butylene glycol/water (20/80, v/v); ethanol (100%), ethanol/water (85/15, v/v), ethanol/water (50/50, v/v); water (100%).
- Plant extracts prepared as described in Example Vffi were tested for their ability to inhibit MMP-I, MMP-2, MMP-3, MMP-9 and/or HLE using the assays described above (Example II).
- This example describes a method of testing the plant extracts for their cytotoxicity and allows non-cytotoxic concentrations of the extracts suitable for further efficacy studies to be selected. Plant extracts were prepared as described in Example VIII.
- Fibroblasts were first grown in a 96-well plate using the complete Ml 06 (Ml 06 + LSGS; Cascade Biologies). This media was also used as control. GM6001 (Chemicon, Temecula, CA) was used as positive control at a concentration of 50 ⁇ M. All extracts and controls were diluted in complete M106. Plant extracts were used at the concentration that provided 100% viability of fibroblasts as shown in Table 10. Cells were seeded into 96-well plates at a concentration of 5X10 3 cells/well in complete M106 media. Plates were incubated for 72 hours at 37°C in a humidified 5% CO 2 atmosphere. After incubation, the medium was removed and 200 ⁇ l of sample were added to the wells (all in duplicate). Plates were incubated for 48 hours at 37°C in a humidified 5% CO 2 atmosphere.
- the ELISA was performed following the protocol recommended by the manufacturer (Takara Biomedicals). 20 ⁇ l of the supernatant from each well were used. Standard buffer and stop solutions were freshly prepared. 100 ⁇ l of the antibody-POD conjugate was added into the wells of the pre-coated 96-well plate, then the 20 ⁇ l of standard and specimens were added to appropriate wells. The plate was mixed gently, sealed (to limit evaporation) and incubated for 3 hours at 37°C.
- each well was washed four times with PBS buffer. 100 ⁇ l of the substrate solution containing hydrogen peroxide and tetramethylbenzidine (TMBZ) was added to each well and the plate was incubated for 15 minutes. After incubation 100 ⁇ l of IN H 2 SO 4 (stop solution) was added to each well. The plate was then gently mixed and the absorbance was read at 450 nm on the Spectrafluor Plus plate reader (Tecan). The reading was taken within 15 minutes of addition of the stop solution. All solutions used were included in the kit except for the PBS and the stop solution.
- TMBZ tetramethylbenzidine
- the following example demonstrates the ability of exemplary extracts prepared as described in Example VIII to inhibit dermal contraction in an in vitro skin model.
- the skin model comprises human skin fibroblasts imbedded in a collagen I matrix and provides an in vitro representation of dermal contraction resulting from tractional forces generated by fibroblasts. Partial or permanent dermal contraction can play a role in the formation of wrinkles.
- extracts capable of inhibiting this type of contraction have the potential to provide a dermo-decontraction anti-ageing effect in the skin.
- These extracts also have potential application in wound healing where pathological scarring is observed by excessive contraction.
- exemplary plant extracts to inhibit dermal contraction was evaluated on human skin fibroblasts (Cascade Biologies, Portland, OR).
- the cells were imbedded in a collagen I matrix to create a derm-like environment.
- Fibroblasts were grown in complete Ml 06 to 80% confluence.
- Free-floating fibroblast-populated collagen gels were prepared in 24-well plates. 500 ⁇ l of gel contains 2.5mg/ml of collagen I collagen I (rat tail, BD Biosciences, Bedford, MA), M106 5X, NaOH 0.7N; IXlO 5 cells and fetal bovine serum (FBS) at 20 % (Wisent, St-Bruno, QC, Canada). The mix was kept on ice until distribution.
- FBS fetal bovine serum
- the derm-like gels were allowed to polymerize for 1 hour at 37°C in a humidified 5% CO 2 atmosphere. After incubation, the gels were detached from the wells. Media 106 was used as negative control and GM6001 (Chemicon, Temecula, CA) at a concentration of 50 ⁇ M was used as positive control.
- FBS at a final concentration of 10% was added to each well.
- the plate was incubated for a maximum of 7 days at 37 0 C in a humidified 5% CO 2 atmosphere. All assays were performed in duplicate. Contraction was measured beginning at day 3. Contracting gels were digitally photographed and the gel areas were calculated using ImagePro software.
- Example VIII demonstrates the non-irritating behaviour of representative plant extracts of the invention prepared as described in Example VIII.
- the amount of Interleukin-8 (IL-8) released after exposure of keratinocytes to a plant extract, as described below, can be used to quantify any possible irritation reaction to the extract.
- IL-8 Interleukin-8
- IL-8 release was evaluated in human skin keratinocytes (Cascade Biologies, Portland, OR) using the Quantikine hIL-8 ELISA kit (R&D Systems, Minneapolis, MN). Keratinocytes were first grown in a 96-well plate using the complete Ml 54 (Ml 54 + HKGS from Cascade Biologies). This media was also used as control. Phorbol 12- myristate 13-acetate (PMA) (Sigma- Aldrich Canada, Oakville, Ontario) at a concentration of 2.5 ⁇ M was used as a positive control. All tested plant extracts and the controls were diluted in complete Ml 54 at a non-cytotoxic concentration ⁇ i.e.
- PMA Phorbol 12- myristate 13-acetate
- the ELISA was performed using following the protocol recommended by the manufacturer (R&D Systems). 25 ⁇ l of the supernatant from each well was mixed with 25 ⁇ l of R5DP IX diluting buffer. Standards were freshly prepared in R5DP IX. 100 ⁇ l of assay diluent RD 1-8 was added to each well of 96-well plate, then the 50 ⁇ l of standard and specimens were added to appropriate wells. The plate was mixed gently, sealed (to limit evaporation) and incubated for 2 hours at room temperature (RT°).
- each well was washed four times with wash buffer. 100 ⁇ l of the conjugation solution was added and incubated for 1 hour at RT 0 . After this incubation, each well was washed four times with wash buffer. 200 ⁇ l of substrate solution containing hydrogen peroxide and tetramethylbenzidine (TMBZ) was added to each well and the plate was incubated for 15 minutes. After incubation, 50 ⁇ l of 2N H 2 SO 4 (stop solution) was added to each well. The plate was then gently mixed and the absorbance read at 450 run on the Spectrafluor Plus plate reader (Tecan). The reading was taken within 15 minutes following addition of the stop solution. AU solutions employed were provided in the kit.
- Keratinocytes were first grown in 24-well plates using the complete Ml 54 (Ml 54 + HKGS from Cascade Biologies) at a concentration of 2.5X10 4 cells/500 ⁇ l/well. The plates were incubated 48 hours at 37°C in a humidified 5% CO 2 atmosphere. The media was removed and the cells were washed 2 times with HBSS. After complete removal of liquid the cells were irradiated with 25 J/cm 2 of UVA light. After irradiation, test samples were added at 500 ⁇ l/well. The media was used as a negative control. GM6001 at a concentration of 50 ⁇ M was used as a positive control.
- Ml 54 Ml 54 + HKGS from Cascade Biologies
- AU extracts and controls were diluted in complete Ml 54 at a non-cytotoxic concentration (i.e. the concentration that provided 100% viability of keratinocytes as shown in Table 10). Plates were incubated for 24 hours at 37°C in a humidified 5% CO 2 atmosphere. The supernatant from each well was assayed or kept at -80°C until use. Supernatants (60 ⁇ l) were assayed for their overall proteolytic activity using the MMP2/7 internally quenched peptide (Calbiochem). All assays were performed in duplicate except for controls, which were performed in quadruplicate.
- ethanol is not commonly used as a solvent in cosmetic formulations
- plant extracts prepared by ethanolic extractions as described in Example VIII can undergo further treatments to prepare them for incorporation into topical formulations.
- the ethanolic extracts can be de-colourised by treatment with activated charcoal following standard protocols.
- the ethanol can be removed from extracts, or de ⁇ colourised extracts and the reduced extract material resuspended on a solid support or in a liquid solvent that is more acceptable to cosmetic formulators.
- the extracts, or de-colourised extracts can be submitted to an evaporation procedure (for example using a rotary evaporator or soxlet) to remove some, or all, of the ethanol component of the solvent.
- a dermatologically suitable alcohol such as a glycol, can be added and the resulting solution incorporated into a carrier suitable for topical application. The activity of the extract may be verified at one or several points in this additional procedure.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2004/002007 WO2006053415A1 (en) | 2004-11-18 | 2004-11-18 | Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof |
EP04822419A EP1819356A4 (en) | 2004-11-18 | 2004-11-18 | Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof |
CA002629529A CA2629529A1 (en) | 2004-11-18 | 2004-11-18 | Plant extracts and dermatological uses thereof |
US10/533,025 US20070122492A1 (en) | 2004-11-18 | 2004-11-18 | Plant extracts and dermatological uses thereof |
JP2007541592A JP2008520588A (en) | 2004-11-18 | 2004-11-18 | Plant extract and its dermatological usage |
US12/970,840 US20110311661A1 (en) | 2003-11-18 | 2010-12-16 | Plant Extracts and Dermatological Uses Thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2004/002007 WO2006053415A1 (en) | 2004-11-18 | 2004-11-18 | Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/970,840 Continuation US20110311661A1 (en) | 2003-11-18 | 2010-12-16 | Plant Extracts and Dermatological Uses Thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006053415A1 true WO2006053415A1 (en) | 2006-05-26 |
Family
ID=36406790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2004/002007 WO2006053415A1 (en) | 2003-11-18 | 2004-11-18 | Plant extract having matrix metalloprotease inhibiting activity and dermatological uses thereof |
Country Status (5)
Country | Link |
---|---|
US (2) | US20070122492A1 (en) |
EP (1) | EP1819356A4 (en) |
JP (1) | JP2008520588A (en) |
CA (1) | CA2629529A1 (en) |
WO (1) | WO2006053415A1 (en) |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006109888A1 (en) * | 2005-04-13 | 2006-10-19 | Shiseido Company, Ltd. | Antiwrinkle agent |
WO2007075750A3 (en) * | 2005-12-20 | 2007-11-01 | Johnson & Johnson Consumer | Compositions containing cotinus coggygria extract and use thereof in treating wounds |
DE102006041486A1 (en) * | 2006-09-02 | 2008-03-06 | Küchenmeister, Kurt-Dieter | Cosmetic and dermatological composition comprises olive oil, yellow petroleum jelly, royal jelly and jerusalem artichoke distillate |
JP2008069074A (en) * | 2006-09-12 | 2008-03-27 | Kyoei Kagaku Kogyo Kk | Cosmetic |
WO2008046140A1 (en) * | 2006-10-17 | 2008-04-24 | Summa Development Limited | Improved treatment for benign prostatic hyperplasia |
FR2910815A1 (en) * | 2006-12-28 | 2008-07-04 | Expanscience Sa Lab | Composition, useful to prepare dermatological composition or functional food, to prevent and treat e.g. irritative, inflammatory or allergic diseases, comprises quinoa seed extract, where the extract is peptidic and osidic/liquid extract |
DE102007032662A1 (en) * | 2007-07-13 | 2009-01-22 | Beiersdorf Ag | Formulation for protecting skin aging caused by intrinsic or extrinsic factors, and for treating itching skin and atopic eczema, has apiogalacturonan or apiogalacturonan containing extract of Zostera marina and one or multiple hydrocolloids |
FR2918881A1 (en) * | 2007-07-18 | 2009-01-23 | Seppic Sa | Use of Parsnip extract as an agent for preparing the drug to prevent the formation of new fat in human body, in a cosmetic composition comprising a medium |
WO2009056614A1 (en) * | 2007-10-30 | 2009-05-07 | Chiracon Gmbh | Vegetable biocatalysts for the production of optically-active hydroxy compounds |
WO2009121168A1 (en) * | 2008-04-01 | 2009-10-08 | Biopharmacopae Design International Inc. | Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection |
FR2933294A1 (en) * | 2008-07-01 | 2010-01-08 | Limousine D Applic Biolog Dite | Cosmetic use of at least one extract from plant of Chenopodium genus as active ingredient in cosmetic composition to improve and/or strengthen skin barrier function, and to increase synthesis of enzymes acting on epidermal lipids synthesis |
JP2010510267A (en) * | 2006-11-24 | 2010-04-02 | ディーエスエム アイピー アセッツ ビー.ブイ. | Composition comprising carnosic acid 12-methyl ether |
US7754248B2 (en) | 2004-10-26 | 2010-07-13 | Johnson & Johnson Consumer Companies, Inc. | Ingestible compositions containing extracts |
FR2941373A1 (en) * | 2010-04-09 | 2010-07-30 | Clarins Lab | Use of Thymus citriodorus extract in cosmetic composition or for preparing dermatological composition to stimulate the synthesis of elastin microfibril interface located protein, and prevent and reduce the release of skin due to pregnancy |
EP2216074A1 (en) | 2009-02-07 | 2010-08-11 | Cognis IP Management GmbH | Dolichos biflorus extract for use in cosmetic skin treatment |
EP2218455A1 (en) | 2009-02-07 | 2010-08-18 | Cognis IP Management GmbH | Dolichos biflorus extract for use in therapeutic skin treatment |
US20100209407A1 (en) * | 2007-06-06 | 2010-08-19 | Basf Beauty Care Solutions France S.A.S. | Mc-1r, mc-2r, and/or mu opioid receptors modulation |
US8137714B2 (en) | 2008-07-25 | 2012-03-20 | Mary Kay Inc. | Compositions comprising docynia delavajy extract and/or Elaeagnus lancelotus extract |
ITMI20101833A1 (en) * | 2010-10-08 | 2012-04-09 | Velleja Res Srl | METHOD FOR THE PREPARATION OF TOTAL EXTRACTS FROM MEDICINAL OR FOOD PLANTS VIA FRACTIONAL EXTRACTION |
KR101147657B1 (en) | 2010-06-15 | 2012-05-23 | (주)에이씨티 | Slimming cosmetic compositions containing natural complex extract and preparing method thereof |
CN101411469B (en) * | 2008-12-02 | 2012-06-06 | 富力 | Potentilla anserina extract food as well as processing technique and uses thereof |
WO2012076977A1 (en) * | 2010-12-10 | 2012-06-14 | Rode Pharma S.R.L. | Method of extracting active molecules from natural resins and use thereof |
ITMI20102318A1 (en) * | 2010-12-17 | 2012-06-18 | Orsola Valeria Urzi | USE OF AN EXTRACT OF SOLANUM MELONGENA L. FOR THE TREATMENT OF WARTS |
KR101201921B1 (en) * | 2010-02-02 | 2012-11-15 | (주)에이씨티 | Slimming cosmetic compositions containing fagopyrum tataricym sprout extracts and preparing method thereof |
US8440237B2 (en) | 2009-04-27 | 2013-05-14 | Mary Kay Inc. | Botanical anti-acne formulations |
EP2633887A1 (en) * | 2011-11-29 | 2013-09-04 | Henkel AG&Co. KGAA | Novel agent combination for efficient anti-wrinkle effect |
JP2014177498A (en) * | 2007-02-13 | 2014-09-25 | Legacy Healthcare Ltd | Method for controlling and/or stabilizing conditions which affect skin |
KR101474216B1 (en) | 2007-09-19 | 2014-12-18 | 코스맥스 주식회사 | Cosmetic compositions used for antiaging and antiwrinkle |
WO2015031971A2 (en) | 2013-09-09 | 2015-03-12 | Natura Cosméticos S.A. | A composition comprising guaçatonga extract and aroeira extract/ use thereof and a method for preventing and/or treating signals caused by skin aging |
US9101555B1 (en) | 2007-04-19 | 2015-08-11 | Mary Kay Inc. | Magnolia extract containing compositions |
US9138401B2 (en) | 2011-12-19 | 2015-09-22 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
EP3135341A1 (en) | 2015-08-27 | 2017-03-01 | Latvijas Universitate | Cosmetic skin whitening compositions containing extracts derived from in vitro propagated hypericum hirsutum |
EP3342465A1 (en) | 2016-12-30 | 2018-07-04 | Bayer Consumer Care AG | Hedychium extract and compositions thereof and their use in the treatment of skin affected by harmful environmental influences |
CN108739873A (en) * | 2018-07-13 | 2018-11-06 | 李�杰 | A kind of auxiliary treatment tinea pedis uses insole cleaning solution |
WO2019000067A1 (en) * | 2017-06-30 | 2019-01-03 | Natura Cosméticos S.A. | Skin tone-correcting cosmetic composition, use of a cosmetic composition and method for correcting the skin tone in an urban environment |
KR20190050927A (en) * | 2017-07-21 | 2019-05-14 | 티씨아이 코 엘티디 | Use of Mimosa pudica extracts for manufacture of composition for inhibiting MMP2 gene expression and collagen degradation |
WO2019110887A1 (en) | 2017-12-08 | 2019-06-13 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | Novel method for reducing the effects of blue-light-induced stress on the skin |
CN110455951A (en) * | 2019-08-19 | 2019-11-15 | 中国农业科学院烟草研究所 | A kind of Tobacco Plastid Pigment analysis method |
US10500152B2 (en) | 2014-03-10 | 2019-12-10 | Mary Kay Inc. | Skin lightening compositions |
DE102019212644A1 (en) * | 2019-08-23 | 2021-02-25 | Beiersdorf Ag | Use of bay leaf extract for the care or treatment of diabetic skin and / or aged skin |
CN112552387A (en) * | 2020-12-31 | 2021-03-26 | 山西大学 | Anti-tumor active protein of day lily and preparation method and application thereof |
CN114470868A (en) * | 2022-02-22 | 2022-05-13 | 瑞昌市渝瑞实业有限公司 | Method and system for separating allantoin from yam mucus and method for preparing skin lotion |
WO2022153337A1 (en) * | 2021-01-16 | 2022-07-21 | Diabliss Consumer Products Pvt Ltd | A nutraceuticals formulation with an enhanced organoleptic properties used for skin care |
CN115177570A (en) * | 2022-08-17 | 2022-10-14 | 科乐美(广州)生物科技有限公司 | Composition with soothing and repairing effects and preparation method and application thereof |
Families Citing this family (181)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006146490A (en) * | 2004-11-18 | 2006-06-08 | Ricoh Co Ltd | Print controller and print control program |
CA2588180A1 (en) * | 2004-12-17 | 2006-06-22 | Bionovo, Inc. | Method of using extracts of epimedium species |
US7482029B2 (en) | 2005-04-01 | 2009-01-27 | Bionovo, Inc. | Composition for treatment of menopause |
US7700136B2 (en) * | 2005-11-14 | 2010-04-20 | Bionovo, Inc. | Scutellaria barbata extract for the treatment of cancer |
WO2007125578A1 (en) * | 2006-04-27 | 2007-11-08 | Noevir Co., Ltd. | Moisturizing agent, skin whitening agent and slimming agent |
US20080025930A1 (en) * | 2006-07-31 | 2008-01-31 | Hugo Corstjens | Anti-aging Compositions Comprising Menyanthes Trifoliata Leaf Extracts and Methods of Use Thereof |
US9925134B2 (en) * | 2006-10-17 | 2018-03-27 | Basf Beauty Care Solutions France Sas | Use of substances to protect FGF-2 or FGF-beta growth factor |
WO2008152624A2 (en) * | 2007-06-15 | 2008-12-18 | Antaki Center For Herbal Medicine Ltd | Herbal energy-enhancing formulation |
US20090042818A1 (en) * | 2007-06-22 | 2009-02-12 | Bionovo, Inc. | Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists |
US20080319051A1 (en) * | 2007-06-22 | 2008-12-25 | Bionovo, Inc. | Liquiritigenin and derivatives as selective estrogen receptor beta agonists |
US8293291B2 (en) * | 2007-06-25 | 2012-10-23 | Smith Walter P | Methods and compositions for reducing the appearance of dynamic facial wrinkles |
IL184312A0 (en) * | 2007-06-28 | 2008-01-20 | Ascarit Ltd | Herbal compositions for the treatment of diabetes and/or conditions associated therewith |
KR101125392B1 (en) | 2007-07-13 | 2012-03-27 | 최윤하 | Cosmetic Composition comprising Extracts of Aronia mandschurica |
AU2008285325A1 (en) * | 2007-08-08 | 2009-02-12 | Bionovo, Inc. | Extracts of Ligustrum lucidum and uses thereof |
KR100903030B1 (en) * | 2007-08-23 | 2009-06-18 | 주식회사 안지오랩 | A fraction of Melissa leaf extract and a composition comprising the same |
WO2009033099A1 (en) * | 2007-09-07 | 2009-03-12 | Bionovo, Inc. | Estrogenic extracts of astragalus membranaceus fisch.bge.var.mongolicus bge. of the leguminosae family and uses thereof |
US9155770B2 (en) * | 2007-09-07 | 2015-10-13 | Bionovo, Inc. | Estrogenic extracts of Scuttelaria barbata D. don of the labiatae family and uses thereof |
JP2010538090A (en) * | 2007-09-07 | 2010-12-09 | バイオノボ・インコーポレーテッド | Estrogenic extracts of Lilyaceae families and their use |
US9132161B2 (en) * | 2007-09-07 | 2015-09-15 | Bionovo, Inc. | Estrogenic extracts of Rheum palmatum L of the polygonaceae family and uses thereof |
CA2698739A1 (en) * | 2007-09-07 | 2009-03-12 | Bionovo, Inc. | Estrogenic extracts of pueraria lobata willd. ohwi of the leguminosae family and uses thereof |
ES2425767T3 (en) * | 2007-09-21 | 2013-10-17 | Pharmabrand S.A. | Herbal composition stimulating the immune, anti-tumor and anti-AIDS system and its elaboration process |
KR20090041532A (en) * | 2007-10-24 | 2009-04-29 | 한국과학기술연구원 | A composition comprising pentaphylloides fruticosa extract as an active ingredient |
US9241893B2 (en) * | 2007-11-19 | 2016-01-26 | Stiefel Laboratories, Inc. | Topical cosmetic skin lightening compositions and methods of use thereof |
AU2008329902A1 (en) | 2007-11-19 | 2009-06-04 | Bionovo, Inc. | A process of making purified extract of scutellaria barbata D. Don |
US9364424B2 (en) | 2007-11-19 | 2016-06-14 | Stiefel Laboratories, Inc. | Topical cosmetic skin lightening compositions and methods of use thereof |
WO2009067553A1 (en) * | 2007-11-19 | 2009-05-28 | Bionovo, Inc. | Anti-cancer therapy with an extract of scutellaria barbata |
CA2706313A1 (en) | 2007-11-19 | 2009-05-28 | Bionovo, Inc. | Methods of detecting and treatment of cancers using scuttelaria barbata extract |
US20090130118A1 (en) * | 2007-11-19 | 2009-05-21 | Bionovo, Inc. | Scutellaria barbata extract and combinations for the treatment of cancer |
KR101127190B1 (en) | 2008-02-05 | 2012-03-29 | (주)파이온텍 | Cosmetic composition containing medical plant feeling powder |
CA2723403A1 (en) * | 2008-05-06 | 2009-11-12 | Bionovo, Inc. | Estrogenic extracts for use in treating vaginal and vulvar atrophy |
WO2009149411A2 (en) * | 2008-06-05 | 2009-12-10 | Bionovo, Inc. | Method of quantification of multiple bioactives from botanical compositons |
US20090312437A1 (en) * | 2008-06-06 | 2009-12-17 | Bionovo, Inc., A Delaware Corporation | Anthraquinones and Analogs from Rhuem palmatum for Treatment of Estrogen Receptor Beta-Mediated Conditions |
JP2010018546A (en) * | 2008-07-10 | 2010-01-28 | Nippon Zettoc Co Ltd | Collagenase inhibitor, external preparation for skin, oral composition and food |
US20100034763A1 (en) * | 2008-08-05 | 2010-02-11 | Conopco, Inc., D/B/A Unilever | Skin Lightening Composition Comprising CO2 Extracts |
WO2010022393A1 (en) * | 2008-08-22 | 2010-02-25 | P.V. Creations | Personal care products containing rainwater |
WO2010028187A2 (en) * | 2008-09-03 | 2010-03-11 | Bionovo, Inc. | Methods and compositions for the treatment of cancer |
JP5970148B2 (en) * | 2008-09-12 | 2016-08-17 | 丸善製薬株式会社 | Tyrosinase activity inhibitor, melanin production inhibitor, and SCF mRNA expression inhibitor |
JP2012509257A (en) * | 2008-11-19 | 2012-04-19 | スティーフェル ラボラトリーズ インコーポレイテッド | Topical whitening cosmetic composition and method of use |
FR2940618B1 (en) * | 2008-12-29 | 2011-06-03 | Fabre Pierre Dermo Cosmetique | NOVEL ACANTH EXTRACT, PROCESS FOR PREPARING THE SAME AND USE THEREOF IN A HAIR COSMETIC COMPOSITION |
US7592024B1 (en) * | 2008-12-29 | 2009-09-22 | Avon Products, Inc. | Topical compositions containing melicope hayselii and a method of treating skin |
US20100166677A1 (en) | 2008-12-30 | 2010-07-01 | Avon Products, Inc. | Use of Tiliacora Triandra in Cosmetics and Compositions Thereof |
JP5479498B2 (en) * | 2009-02-10 | 2014-04-23 | ピオン−テック・カンパニー・リミテッド | Cosmetic composition comprising herbal peeling powder having DDS mechanism |
WO2010106417A2 (en) * | 2009-03-16 | 2010-09-23 | Himalaya Global Holdings Ltd. | Herbal personal care formulations and method of preparing the same |
FR2943542B1 (en) * | 2009-03-31 | 2012-05-25 | Lvmh Rech | METHOD OF ANTI-AGE COSMETIC CARE BY STIMULATING THE ACTIVITY OF MITOCHONDRIAL ACONISATE |
FR2943535B1 (en) * | 2009-03-31 | 2011-08-12 | Lvmh Rech | NEW USE OF A PLANT EXTRACT OBTAINED FROM AT LEAST ONE PLANT BELONGING TO THE GENUS CITRUS, OR A HYBRID FROM THE CROSSING OF VEGETABLE SPECIES OF WHICH AT LEAST ONE APPEARS TO THE GENUS CITRUS. |
FR2944703B1 (en) * | 2009-04-22 | 2012-12-21 | Clarins Lab | ANTI AGE COSMETIC COMPOSITION |
US20100303936A1 (en) * | 2009-04-28 | 2010-12-02 | Bionovo, Inc. A Delaware Corporation | Method of reducing fat accumulation and inducing weight loss |
FR2945213B1 (en) * | 2009-05-07 | 2015-10-16 | Rocher Yves Biolog Vegetale | COSMETIC AND DERMATOLOGICAL AND DERMATOLOGICAL COMPOSITIONS BASED ON SILENE EXTRACT. |
KR101601908B1 (en) * | 2009-05-07 | 2016-03-10 | (주)아모레퍼시픽 | Composition containing snowberry extract |
KR101131488B1 (en) * | 2009-06-11 | 2012-04-19 | 주식회사 오비엠랩 | Skin care compositions for antiwrinkle effect |
WO2010150245A1 (en) * | 2009-06-24 | 2010-12-29 | Tikun Olam Ltd. | Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts |
TR200908386A2 (en) * | 2009-11-05 | 2010-06-21 | Mci İlaç Ve Kozmeti̇k Ürünleri̇ İmalat Ti̇c. Ltd. Şti̇. | Dermatological composition for the treatment of skin burns, skin diseases and infected wounds |
US8496948B2 (en) * | 2009-12-02 | 2013-07-30 | Bath And Body Works Brand Management, Inc. | Topical skin composition comprising mineral yeast ferments |
WO2011083397A1 (en) * | 2010-01-05 | 2011-07-14 | Himalaya Global Holdings Limited | Herbal composition for skin disorders |
JP2011168559A (en) * | 2010-02-22 | 2011-09-01 | Noevir Co Ltd | Antioxidant, anti-inflammatory agent, anti-aging agent, skin care preparation for external use and functional oral composition |
JP2011225550A (en) * | 2010-03-30 | 2011-11-10 | Cci Corp | Matrix metalloprotease production suppressing and elastase activity inhibiting agent |
JP5675178B2 (en) * | 2010-06-09 | 2015-02-25 | 大島 光宏 | Collagen degradation inhibitor |
US20110305737A1 (en) * | 2010-06-09 | 2011-12-15 | NY Derm LLC | Multi-Active Microtargeted Anti-Aging Skin Cream Polymer Technology |
AU2011276479B2 (en) | 2010-06-28 | 2015-06-25 | Stemtech International, Inc. | Methods and compositions for enhancing stem cell mobilization |
US8771758B2 (en) * | 2010-06-30 | 2014-07-08 | Avon Products, Inc. | Use of Tiliacora triandra in cosmetics and compositions thereof |
EP2601959B1 (en) * | 2010-08-06 | 2018-11-21 | Shiseido Company, Ltd. | Elastase inhibitor |
US8435541B2 (en) | 2010-09-02 | 2013-05-07 | Bath & Body Works Brand Management, Inc. | Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities |
KR101191724B1 (en) | 2010-10-07 | 2012-10-16 | 재단법인 한국한방산업진흥원 | Composition comprising a leaf extract of Isatis indigotica Fort showing skin whitening and anti-wrinkle activity |
KR101256222B1 (en) | 2010-10-28 | 2013-04-19 | 한국원자력연구원 | Method for removing the pigment of Red beet extract using irradiation |
US20130337090A1 (en) * | 2010-11-07 | 2013-12-19 | Skin Matrix Ltd. | Plant extracts for treating burns and chronic wounds |
US10744151B1 (en) | 2010-12-01 | 2020-08-18 | Gowey Research Group PLLC | Micro-RNA profiling, compositions, and methods of treating diseases |
US10758578B2 (en) * | 2010-12-01 | 2020-09-01 | Gowey Research Group PLLC | Herbal formulations of carnivorous plants and methods for treating inflammation |
US11414663B2 (en) | 2010-12-01 | 2022-08-16 | Gowey Research Group, Pllc | Micro-RNA profiling, compositions, and methods of treating diseases |
WO2012075275A2 (en) * | 2010-12-01 | 2012-06-07 | Brandy Gowie | Novel topical composition of sarracenia purpurea (pitcher plant) |
US11344505B1 (en) * | 2010-12-01 | 2022-05-31 | Gowey Research Group, Pllc | Herbal formulations of carnivorous plants and methods for treating inflammation |
WO2012077976A2 (en) * | 2010-12-07 | 2012-06-14 | 한국생명공학연구원 | Anti-aging composition containing elaeocarpus petiolatus extract or fraction thereof as active ingredient |
JP2012171877A (en) * | 2011-02-18 | 2012-09-10 | Kose Corp | Antioxidant, agent for improving skin turgor or sagging, radical scavenger and elastase activity inhibitor |
JP2012171932A (en) * | 2011-02-23 | 2012-09-10 | Kao Corp | Aromatase activator |
JP2012176923A (en) * | 2011-02-28 | 2012-09-13 | Kose Corp | Antioxidant, tenseness- and slack-ameliorating agent, radical scavenger, elastase activity inhibitor and antiaging agent |
EP2680870A4 (en) * | 2011-03-01 | 2015-09-02 | Phytomedics Corp Inc | Methods of processing extracts of a t. wilfordii hook f. plant |
CN108403521B (en) * | 2011-03-28 | 2022-02-11 | 玫琳凯有限公司 | Topical skin compositions and uses thereof |
CN106176348A (en) | 2011-04-06 | 2016-12-07 | 玫琳凯有限公司 | Topical skin composition and the method processing skin |
US8444959B2 (en) * | 2011-04-21 | 2013-05-21 | Mary Kay Inc. | Topical skin care formulations comprising plant extracts |
DE102011101875A1 (en) | 2011-05-18 | 2012-11-22 | Merck Patent Gmbh | Extracts from Darlingtonia californica |
KR101312965B1 (en) * | 2011-05-20 | 2013-09-27 | 이상록 | The cosmetic composition for anti-wrinkle comprising the mixture of extract of Allium cepa, Symphytum officinale, Eclipta prostrate, and Theobroma cacao |
KR101242442B1 (en) | 2011-06-21 | 2013-03-12 | 주식회사 마크로케어 | Cosmetic Composition Comprising Extracts of Fermented Setaria italica |
JP5872805B2 (en) * | 2011-07-07 | 2016-03-01 | 花王株式会社 | MFAP-4 production promoter |
CA2841133A1 (en) | 2011-08-05 | 2013-02-14 | Stemtech International, Inc. | Skin care compositions containing combinations of natural ingredients |
KR101257435B1 (en) | 2011-08-09 | 2013-04-23 | 이상록 | The cosmetic composition for alleviating atopy and contact dermatitis containing sage, Melissa officinalis, Gelidium amansii and Allium cepa |
EA201490995A1 (en) * | 2011-11-18 | 2014-08-29 | Стемтек Интернэшнл, Инк. | USE OF FO-TI TO ENHANCE MOBILIZATION AND PROLIFERATION OF STEM CELLS |
US20130164234A1 (en) * | 2011-12-22 | 2013-06-27 | Lonza Walkersville, Inc. | Composition for treating skin pigmentation |
WO2013126107A1 (en) * | 2012-02-24 | 2013-08-29 | Nowsystem, Inc. | Improved compositions and related methods for oral wellness |
CN104125832A (en) * | 2012-02-29 | 2014-10-29 | 雅芳产品公司 | Use of starfruit extract as a CPT-1 modulator and compositions thereof |
FR2988296B1 (en) * | 2012-03-23 | 2017-01-27 | Soc D'exploitation De Produits Pour Les Ind Chimiques Seppic | NOVEL USE OF QUINOA EXTRACTS AS AN ACTIVE AGENT FOR PREVENTING AND / OR LIMITING THE INESTHETIC EFFECTS GENERATED BY THE HYPOXIA OF ENDOTHELIAL CELLS OF THE HUMAN BODY |
US9421161B2 (en) | 2012-04-10 | 2016-08-23 | Robert Thomas van Aller | Herbal composition and a method of making thereof |
WO2013173353A1 (en) * | 2012-05-14 | 2013-11-21 | Biocogent, Llc | Prevention of fibroblast collapse |
JP2014005222A (en) * | 2012-06-22 | 2014-01-16 | Kao Corp | MMPs ACTIVITY INHIBITOR |
CN103536823B (en) * | 2012-07-13 | 2016-08-17 | 葛学义 | Treat psoriasic external use traditional Chinese medicine tincture |
US8920855B1 (en) | 2012-10-30 | 2014-12-30 | Setem Hemth, Inc | Methods of topically treating tinnitus and related disorders |
WO2014081976A1 (en) * | 2012-11-21 | 2014-05-30 | Aviratek Biomedical Solutions, Llc | Method and compositions for the use of botanical extracts in the treatment of viral infections, cancer, pain, itch, and inflammation |
WO2014092686A1 (en) * | 2012-12-11 | 2014-06-19 | Avon Products, Inc. | Stephanotis jasminoides extracts and methods of use |
US20140161918A1 (en) * | 2012-12-11 | 2014-06-12 | Avon Products, Inc. | Use of Adipose Septa Protein Modulators and Compositions Thereof |
US9186316B2 (en) | 2012-12-11 | 2015-11-17 | Avon Products, Inc. | Stephanotis jasminoides extracts and methods of use |
KR101705847B1 (en) * | 2013-01-18 | 2017-02-10 | 가천대학교 산학협력단 | A composition for inhibiting degradation of collagen or promoting synthesis of collagen comprising barley extract or eriodictyol |
FR3001391B1 (en) * | 2013-01-29 | 2017-07-07 | Oreal | USE OF ELIDITE IRIDACEE VEGETABLE CELLS IN THE TREATMENT OF SENSITIVE SKIN |
WO2014158789A1 (en) * | 2013-03-14 | 2014-10-02 | Avon Products, Inc | Sesbania aculeata extracts and methods of use |
US20160008265A1 (en) * | 2013-03-14 | 2016-01-14 | Avon Products, Inc | Eurya groffii extracts and methods of use |
JP2014224074A (en) * | 2013-05-16 | 2014-12-04 | 地方独立行政法人北海道立総合研究機構 | Elastase activity inhibitor comprising extracts of salicaceous salix plant |
JP2014224073A (en) * | 2013-05-16 | 2014-12-04 | 地方独立行政法人北海道立総合研究機構 | Elastase activity inhibitor comprising leaf extracts of pinaceae abies plant |
KR20170130643A (en) | 2013-06-28 | 2017-11-28 | 베니 안토니 | A medicinal composition of amaranth extract origin having enriched nitrate content and a method of preparing the same |
US11338005B2 (en) | 2013-06-28 | 2022-05-24 | Arjuna Natural Private Limited | Medicinal composition of amaranth origin for cardiovascular treatment |
EP3024471B1 (en) | 2013-07-22 | 2019-10-30 | Université du Québec à Chicoutimi | Use of plant extracts against herpes simplex virus |
US8835370B2 (en) * | 2013-08-05 | 2014-09-16 | Greenology Products, Inc. | Organic cleaning composition |
US9447366B2 (en) | 2013-08-05 | 2016-09-20 | Greenology Products, Inc. | Organic cleaning composition |
US9217125B2 (en) * | 2013-08-05 | 2015-12-22 | Greenology Products, Inc. | Organic cleaning composition |
US9763873B2 (en) | 2013-08-16 | 2017-09-19 | La Prairie Group Ag | Preparation for protecting against extrinsic and intrinsic skin aging |
US9375463B2 (en) * | 2013-09-10 | 2016-06-28 | Creative Medical Health, Inc. | Compositions and methods for improving sleep using a nutraceutical formulation |
JP5768113B2 (en) * | 2013-11-29 | 2015-08-26 | ポーラ化成工業株式会社 | Method for producing external preparation for skin for pretreatment |
RU2564004C2 (en) * | 2013-12-09 | 2015-09-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Иркутский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method for producing anti-inflammatory agent, version 2 |
RU2564000C2 (en) * | 2013-12-09 | 2015-09-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Иркутский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method for producing anti-inflammatory agent, version 5 |
RU2603511C2 (en) * | 2013-12-24 | 2016-11-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный университет" (Астраханский государственный университет) | Method for producing and fatty acid content of morus nigra seed soil |
KR101636817B1 (en) * | 2014-03-28 | 2016-07-07 | (주)보광코리아 | Pharmaceutical composition for prophylaxis and treatment of acne, skin external preparation, and method for producing extract of physostegia virginiana |
JP6803110B2 (en) * | 2014-03-31 | 2020-12-23 | 日本メナード化粧品株式会社 | External and internal skin preparations containing an extract of nasturtium cultivated by irradiating light with a specific wavelength range |
JP6586691B2 (en) * | 2014-03-31 | 2019-10-09 | 日本メナード化粧品株式会社 | Skin external preparation or internal preparation containing an extract of chervil grown by irradiating light having a specific wavelength range |
JP6513468B2 (en) * | 2014-05-01 | 2019-05-15 | 日本メナード化粧品株式会社 | A skin external preparation or an internal preparation containing an extract of red beet grown by irradiation with light having a specific wavelength range. |
JP6513469B2 (en) * | 2014-05-01 | 2019-05-15 | 日本メナード化粧品株式会社 | The external preparation for skin and the internal preparation containing the extract of the Chinese cabbage which is grown by irradiating the light which has a specific wavelength range. |
KR101685251B1 (en) * | 2014-05-28 | 2016-12-09 | 가천대학교 산학협력단 | Cosmetic composition comprising extract of Brassica Rapa, Brassica Rapa radish leaves or Brassica Rapa callus with anti-oxidant, astringent activity and skin wrinkle improvement effect and the manufacturing method thereof |
CA2952934A1 (en) | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
US9814670B2 (en) | 2014-12-04 | 2017-11-14 | Mary Kay Inc. | Cosmetic compositions |
FR3029416B1 (en) * | 2014-12-09 | 2019-08-16 | Laboratoires Clarins | COSMETIC USE OF AN ESCHOLTZIA CALIFORNICA EXTRACT |
WO2016111552A1 (en) * | 2015-01-06 | 2016-07-14 | 권영아 | Luterion and separating and culturing methods for same |
JP2018503671A (en) * | 2015-02-02 | 2018-02-08 | アイ.ビー.アール.イスラエリ バイオテクノロジー リサーチ リミテッド | Asteriscus gravelens extract and use thereof |
US9849078B2 (en) * | 2015-03-19 | 2017-12-26 | Franklin Kilbert Karbstein | Plant extract for hair tonic for treating baldness and preventing hair loss and hair bulb regenerator |
WO2017015240A1 (en) * | 2015-07-17 | 2017-01-26 | Farma-Blanco, Llc | Herbal composition for body treatment |
KR101637396B1 (en) * | 2015-08-12 | 2016-07-07 | 주식회사 단정바이오 | Cosmetic composition for improving anti-oxidation, anti-inflammatory and atopic skin and method of preparing the same |
US10278914B2 (en) | 2015-08-13 | 2019-05-07 | Coty Inc. | Formulation and method for promoting cutaneous uptake of molecular oxygen by skin |
JP6348890B2 (en) * | 2015-09-16 | 2018-06-27 | オッペン化粧品株式会社 | Decomposition inhibitor, anti-aging agent and topical skin preparation |
US9980998B2 (en) * | 2015-10-07 | 2018-05-29 | Braerg—Grupo Barśileiro De Pesquisas Especializadas Ltda. | Medicinal composition having antibiotic, anti-inflammatory, and wound healing activity |
JP2017088538A (en) * | 2015-11-10 | 2017-05-25 | 日本メナード化粧品株式会社 | Filaggrin production promoter |
FR3044924B1 (en) * | 2015-12-10 | 2019-03-29 | Laboratoires Clarins | COSMETIC USE OF A PHILADELPHUS CORONARIUS EXTRACT |
AU2017200088B2 (en) * | 2016-01-07 | 2021-04-29 | Gowey Research Group PLLC | Herbal formulations of carnivorous plants and methods for treating inflammation |
KR101809016B1 (en) | 2016-02-03 | 2017-12-15 | 재단법인 경기도경제과학진흥원 | Pharmaceutical composition for preventing ortreating diseases or disorders associated within flammation |
AR108116A1 (en) * | 2016-04-11 | 2018-07-18 | Biolab Sanus Farmaceutica Ltda | DERMOCOSMETIC COMPOSITION, PROCESS OF PRODUCTION OF THE TOPICAL COMPOSITION, METHOD FOR STRENGTHENING OF FRAGILE NAILS AND USE OF COMPOSITION |
KR102471845B1 (en) * | 2016-10-04 | 2022-11-28 | 마리 케이 인코포레이티드 | Methods and compositions for the treatment of stretch marks |
EP3538064A4 (en) * | 2016-11-09 | 2019-12-11 | ELC Management LLC | Topical compositions and methods for stimulating mir-146a in skin cells |
BR102016029937A2 (en) * | 2016-12-20 | 2018-07-17 | Natura Cosméticos S.A. | makeup cosmetic makeup, liquid foundation and use of a makeup cosmetic makeup |
JP2018177716A (en) * | 2017-04-17 | 2018-11-15 | 株式会社アイビー化粧品 | Matrix metalloprotease 9 inhibitor and skin external preparation containing the same |
US10293012B2 (en) | 2017-05-04 | 2019-05-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of using extracts of melissa officinalis against filoviruses |
TWI612966B (en) * | 2017-06-06 | 2018-02-01 | 景鑫生物科技股份有限公司 | A use of an extract of asplenium australasicum (j. sm.) hook. |
GB201717712D0 (en) * | 2017-10-27 | 2017-12-13 | Naturex Sa | Compositions |
US20190134129A1 (en) | 2017-11-06 | 2019-05-09 | Sinotai Oncology Associate., Ltd. | Method for alleviating ultraviolet damage with ethyl acetate-extracted product of sedum formosanum |
WO2019099613A1 (en) * | 2017-11-16 | 2019-05-23 | University Of Maine System Board Of Trustees | Compositions and methods for modulating endothelial cell migration and angiogenesis |
KR20200116094A (en) * | 2017-12-28 | 2020-10-08 | 파비안 하바스 | Inula helenium extract for the treatment and prevention of pollution-related damage |
DE102018101861A1 (en) * | 2018-01-26 | 2019-08-01 | Bertrand Prévôt | Cosmetic or pharmaceutical preparation for skin care and for the prophylaxis of muscle cramps |
KR102628074B1 (en) * | 2018-06-01 | 2024-01-25 | 애경산업(주) | skin external application composition for anti-aging containing Luzula capitate extract |
US11191716B1 (en) * | 2018-09-20 | 2021-12-07 | Phisao | Process for preparing potent plant based cosmetic actives and application to an antiperspirant active |
KR102125409B1 (en) * | 2018-10-04 | 2020-06-22 | 주식회사 코리아나화장품 | Cosmetic Composition for Improving Skin Wrinkle Contaning the Extract of Fermented Vibumum Opulus |
RU2704490C1 (en) * | 2018-11-12 | 2019-10-29 | Общество с ограниченной ответственностью "НАТУРА СИБЕРИКА" (ООО "НАТУРА СИБЕРИКА") | Anti-prolapse composition and stimulating hair growth |
KR102277183B1 (en) * | 2018-11-22 | 2021-07-14 | 한국 한의학 연구원 | Composition for improving skin wrinkle and skin moisturizing comprising Dolichos lablab extract as effective component |
US20200237626A1 (en) * | 2019-01-28 | 2020-07-30 | Jamrm, Llc | Anti-Aging Corrective and Protective Formulation and Methods |
KR101998804B1 (en) * | 2019-03-05 | 2019-07-10 | 에스앤에프 주식회사 | Antioxidant and anti-aging composition |
KR102193317B1 (en) * | 2019-03-12 | 2020-12-22 | 주식회사 엔에스웰니스 | Composition for obesity treatment and improvement |
JPWO2020203217A1 (en) * | 2019-03-29 | 2020-10-08 | ||
KR102010235B1 (en) * | 2019-06-07 | 2019-08-13 | 조봉상 | Cosmetic composition having skin whitening effect |
KR20210003473A (en) * | 2019-07-02 | 2021-01-12 | (주)아모레퍼시픽 | Composition for enhancing skin elasticity or improving skin wrinkles comprising heptahydroxyflavan as an effective ingredient |
AU2020328061A1 (en) | 2019-08-14 | 2022-03-24 | Ge Nutrients, Inc. | Herbal preparation for stimulation of hair growth, control of hair fall, dandruff and infections thereof using Ageratum spp. |
WO2021054971A1 (en) * | 2019-09-20 | 2021-03-25 | Menetrier David Benoit Camille | Process for preparing potent plant based cosmetic actives and application to an antiperspirant active |
KR102342136B1 (en) * | 2019-12-27 | 2021-12-24 | 주식회사 디볼베르코스메틱 | Jaw-line correction cosmetic mask pack |
NL2025679B1 (en) * | 2020-05-26 | 2021-12-13 | Johanna Daams Brechtje | Electrical stimulation for preventing or treating nitric oxide deficiency related conditions |
KR102251854B1 (en) * | 2020-08-03 | 2021-05-13 | 최귀남 | Cosmetic composition for skin moisturizing and anti-wrinkle comprising Chamaecyparis obtusa leaf mixed extract as effective component |
KR102528620B1 (en) * | 2020-08-18 | 2023-05-04 | 코스맥스 주식회사 | Composition for preventing or improving Osmidrosis axillae comprising Seed fermented of Lotus spp. plant |
WO2022092124A1 (en) * | 2020-10-28 | 2022-05-05 | 国立大学法人神戸大学 | Matrix metalloprotease 1 expression inhibitor, skin external agent, and use for inhibition of matrix metalloprotease 1 expression |
CN113068827A (en) * | 2021-05-12 | 2021-07-06 | 贾森 | Organic complementary food full-value nutrition bar for infants and preparation method thereof |
CN113509416B (en) * | 2021-07-13 | 2023-04-25 | 无限极(中国)有限公司 | Composition with effect of enhancing catalase activity and application of composition in cosmetics |
KR102622831B1 (en) * | 2021-10-08 | 2024-01-09 | 제주대학교 산학협력단 | A composition for prevention or improvement of hair loss comprising setaria italica beauv. extract |
KR20230050806A (en) * | 2021-10-08 | 2023-04-17 | 제주대학교 산학협력단 | A composition for prevention or treatment of hair loss comprising setaria italica beauv. extract |
CN114259438B (en) * | 2021-12-21 | 2023-11-14 | 上海珈凯生物股份有限公司 | Caper fruit compound liquid and preparation method and application thereof |
KR102565365B1 (en) * | 2022-01-24 | 2023-08-09 | 주식회사 엑소코바이오 | New composition comprising exosomes derived from Nepeta cartaria as an active ingredient |
WO2023140599A1 (en) * | 2022-01-24 | 2023-07-27 | 주식회사 엑소코바이오 | Novel composition comprising nepeta cartaria-derived exosomes as active ingredient |
WO2023167500A1 (en) * | 2022-03-02 | 2023-09-07 | 방기정주식회사 | Cosmetic composition for modified nail care and manufacturing method therefor |
CN114933617B (en) * | 2022-05-06 | 2023-05-23 | 西南民族大学 | Process for preparing benzophenone dimer compounds |
CN115337239B (en) * | 2022-08-31 | 2023-08-18 | 广州研智化妆品有限公司 | Essential oil with relieving and repairing effects and preparation method thereof |
KR102552610B1 (en) * | 2022-09-06 | 2023-07-07 | 주식회사 케어테크 | A composition containing flower extract as an active ingredient, excellent in relieving scalp itchiness, preventing dandruff, and preventing hair loss |
KR102548612B1 (en) * | 2022-12-21 | 2023-06-29 | 주식회사 프롬바이오 | Compositions for Improving Skin Wrinkles and for Skin Moisturizing Using an Extract of Parsnip |
CN116059303B (en) * | 2023-03-03 | 2023-06-13 | 广东青云山药业有限公司 | Composite drynaria extract and preparation process thereof |
US11926446B1 (en) * | 2023-06-16 | 2024-03-12 | Good Foods Group, Llc | System and method for formulating compounds into personal care products |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1179970A (en) * | 1997-09-03 | 1999-03-23 | Shiseido Co Ltd | Collagenase inhibitor |
JPH11240842A (en) * | 1998-02-24 | 1999-09-07 | Shiseido Co Ltd | Protease inhibitor |
JP2000256122A (en) * | 1999-03-03 | 2000-09-19 | Shiseido Co Ltd | Matrix metalloproteinases inhibitor |
JP2001192316A (en) * | 2000-01-06 | 2001-07-17 | Shiseido Co Ltd | Matrix metalloproteinases inhibitor |
JP2001354582A (en) * | 2000-06-16 | 2001-12-25 | Md Japan Kk | Protease inhibitor |
FR2812544A1 (en) * | 2000-08-02 | 2002-02-08 | Oreal | Treatment of cutaneous aging symptoms, such as wrinkles, comprises topical or oral administration of Salvia genus plant extracts with collagenase expression inhibiting activity |
WO2002034231A2 (en) * | 2000-10-26 | 2002-05-02 | L'oreal | Use of the association of at least an plant extract of genus rosmarinus and of at least a carotenoid |
WO2002034276A2 (en) * | 2000-10-26 | 2002-05-02 | L'oreal | Use of the association of at least a plant extract of the genus camellia and of at least a carotenoid |
WO2002069992A1 (en) * | 2001-03-02 | 2002-09-12 | Biopharmacopae Design International Inc. | Plant extracts and compositions comprising extracellular protease inhibitors |
EP1275372A1 (en) * | 2001-06-26 | 2003-01-15 | L'oreal, S.A. | Cosmetic or dermatological composition comprising a N-acylaminoamide derivative and a metalloproteinase inhibitor |
JP2003160433A (en) * | 2001-11-27 | 2003-06-03 | Shiseido Co Ltd | Anti-aging skin preparation for external use |
JP2003201229A (en) * | 2001-10-23 | 2003-07-18 | Shiseido Co Ltd | Matrix metalloprotease activity inhibitor and ageing- resistant cosmetic |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2276241A (en) * | 1939-07-01 | 1942-03-10 | Tannin Corp | Medicinal preparation |
CH662505A5 (en) * | 1985-04-30 | 1987-10-15 | Seuref Ag | Pharmaceutical composition for protective action vascular. |
JPS6290167A (en) * | 1985-10-15 | 1987-04-24 | 松下電工株式会社 | Deodorant |
CN86103972A (en) * | 1986-06-06 | 1987-12-16 | 中国科学院西北高原生物研究所 | Cosmetic mede from sand bramble |
US4963346A (en) * | 1988-05-31 | 1990-10-16 | Amer & Company, Inc. | Method and composition for treatment or prevention of dental plaque calculus and gingivitis |
ES2091192T3 (en) * | 1989-01-05 | 1996-11-01 | Leti Lab | APPLICATION OF SPECIFIC PROPERTIES OF ALLERGENS, ALLERGENS FROM ANIMAL AND VEGETABLE SOURCES AND METHODS FOR THEIR ISOLATION. |
JP2963522B2 (en) * | 1990-10-18 | 1999-10-18 | 株式会社資生堂 | Makeup cosmetics |
JP3479918B2 (en) * | 1992-11-09 | 2003-12-15 | 三和生薬株式会社 | New wetting agent |
JP3159412B2 (en) * | 1992-11-26 | 2001-04-23 | カネボウ株式会社 | Skin cosmetics |
FR2757392B1 (en) * | 1996-12-20 | 1999-05-14 | Dior Christian Parfums | USE OF AN EXTRACT FROM THE PLANT CORDIA DICHOTOMA IN THE COSMETIC AND PHARMACEUTICAL AREAS, ESPECIALLY DERMATOLOGICAL |
JP2002515898A (en) * | 1997-02-25 | 2002-05-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Methods and compositions for preventing and treating aging in human skin |
JP3819126B2 (en) * | 1997-09-19 | 2006-09-06 | 花王株式会社 | Skin preparation for inhibiting sebum synthesis |
JPH11246336A (en) * | 1998-02-27 | 1999-09-14 | Ichimaru Pharcos Co Ltd | Activated oxygen scavenger and skin beautifying cosmetic composition |
JPH11246347A (en) * | 1998-03-05 | 1999-09-14 | Shiseido Co Ltd | Preparation for external use for skin bleaching |
CN1307473A (en) * | 1998-05-19 | 2001-08-08 | 研究发展基金会 | Triterpene compositions and methods for use thereof |
JP2000336024A (en) * | 1999-05-27 | 2000-12-05 | Ichimaru Pharcos Co Ltd | Cosmetic composition containing moisturizing plat extract |
JP2001253831A (en) * | 2000-03-10 | 2001-09-18 | Yukiyo Iwai | Skin care preparation |
US20020119107A1 (en) * | 2000-12-18 | 2002-08-29 | James Varani | Method for protecting and restoring skin using selective MMP inhibitors |
US7078048B2 (en) * | 2001-05-09 | 2006-07-18 | The Regents Of The University Of Michigan | Method and compositions for treating rosacea |
CA2447231A1 (en) * | 2001-05-23 | 2002-11-28 | Hamdi K. Hamdi | Methods for inhibiting angiogenesis |
JP2003306438A (en) * | 2002-02-18 | 2003-10-28 | Shiseido Co Ltd | Chemokine expression inhibitor |
EP1539204A1 (en) * | 2002-08-30 | 2005-06-15 | Biopharmacopae Design International Inc. | Plant extracts for treatment of angiogenesis and metastasis |
JP4262494B2 (en) * | 2003-02-19 | 2009-05-13 | ポーラ化成工業株式会社 | Melanocyte dendrite elongation inhibitor |
US6853489B2 (en) * | 2003-04-10 | 2005-02-08 | Hitachi Via Mechanics, Ltd. | Correction of angular deviation and radial drift of laser beams |
-
2004
- 2004-11-18 EP EP04822419A patent/EP1819356A4/en not_active Withdrawn
- 2004-11-18 JP JP2007541592A patent/JP2008520588A/en active Pending
- 2004-11-18 US US10/533,025 patent/US20070122492A1/en not_active Abandoned
- 2004-11-18 CA CA002629529A patent/CA2629529A1/en not_active Abandoned
- 2004-11-18 WO PCT/CA2004/002007 patent/WO2006053415A1/en active Application Filing
-
2010
- 2010-12-16 US US12/970,840 patent/US20110311661A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1179970A (en) * | 1997-09-03 | 1999-03-23 | Shiseido Co Ltd | Collagenase inhibitor |
JPH11240842A (en) * | 1998-02-24 | 1999-09-07 | Shiseido Co Ltd | Protease inhibitor |
JP2000256122A (en) * | 1999-03-03 | 2000-09-19 | Shiseido Co Ltd | Matrix metalloproteinases inhibitor |
JP2001192316A (en) * | 2000-01-06 | 2001-07-17 | Shiseido Co Ltd | Matrix metalloproteinases inhibitor |
JP2001354582A (en) * | 2000-06-16 | 2001-12-25 | Md Japan Kk | Protease inhibitor |
FR2812544A1 (en) * | 2000-08-02 | 2002-02-08 | Oreal | Treatment of cutaneous aging symptoms, such as wrinkles, comprises topical or oral administration of Salvia genus plant extracts with collagenase expression inhibiting activity |
WO2002034231A2 (en) * | 2000-10-26 | 2002-05-02 | L'oreal | Use of the association of at least an plant extract of genus rosmarinus and of at least a carotenoid |
WO2002034276A2 (en) * | 2000-10-26 | 2002-05-02 | L'oreal | Use of the association of at least a plant extract of the genus camellia and of at least a carotenoid |
WO2002069992A1 (en) * | 2001-03-02 | 2002-09-12 | Biopharmacopae Design International Inc. | Plant extracts and compositions comprising extracellular protease inhibitors |
EP1275372A1 (en) * | 2001-06-26 | 2003-01-15 | L'oreal, S.A. | Cosmetic or dermatological composition comprising a N-acylaminoamide derivative and a metalloproteinase inhibitor |
JP2003201229A (en) * | 2001-10-23 | 2003-07-18 | Shiseido Co Ltd | Matrix metalloprotease activity inhibitor and ageing- resistant cosmetic |
JP2003160433A (en) * | 2001-11-27 | 2003-06-03 | Shiseido Co Ltd | Anti-aging skin preparation for external use |
Non-Patent Citations (7)
Title |
---|
DATABASE WPI Week 1999, Derwent World Patents Index; AN 1999-261412, XP008110530 * |
DATABASE WPI Week 1999, Derwent World Patents Index; AN 1999-594040, XP008110531 * |
DATABASE WPI Week 2000, Derwent World Patents Index; AN 2000-579204, XP008110533 * |
DATABASE WPI Week 2001, Derwent World Patents Index; AN 2000-579204, XP008110533 * |
DATABASE WPI Week 2001, Derwent World Patents Index; AN 2002-262908, XP008110536 * |
DATABASE WPI Week 2003, Derwent World Patents Index; AN 2003-818769, XP008110532 * |
DATABASE WPI Week 2003, Derwent World Patents Index; AN 2003-819640, XP008110534 * |
Cited By (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754248B2 (en) | 2004-10-26 | 2010-07-13 | Johnson & Johnson Consumer Companies, Inc. | Ingestible compositions containing extracts |
WO2006109888A1 (en) * | 2005-04-13 | 2006-10-19 | Shiseido Company, Ltd. | Antiwrinkle agent |
WO2007075750A3 (en) * | 2005-12-20 | 2007-11-01 | Johnson & Johnson Consumer | Compositions containing cotinus coggygria extract and use thereof in treating wounds |
DE102006041486A1 (en) * | 2006-09-02 | 2008-03-06 | Küchenmeister, Kurt-Dieter | Cosmetic and dermatological composition comprises olive oil, yellow petroleum jelly, royal jelly and jerusalem artichoke distillate |
DE102006041486B4 (en) * | 2006-09-02 | 2011-04-28 | Küchenmeister, Kurt-Dieter | Cosmetic and dermatological preparation |
JP2008069074A (en) * | 2006-09-12 | 2008-03-27 | Kyoei Kagaku Kogyo Kk | Cosmetic |
WO2008046140A1 (en) * | 2006-10-17 | 2008-04-24 | Summa Development Limited | Improved treatment for benign prostatic hyperplasia |
JP2010510267A (en) * | 2006-11-24 | 2010-04-02 | ディーエスエム アイピー アセッツ ビー.ブイ. | Composition comprising carnosic acid 12-methyl ether |
JP2013255495A (en) * | 2006-11-24 | 2013-12-26 | Dsm Ip Assets Bv | Composition comprising carnosic acid 12-methylether |
US8680147B2 (en) | 2006-11-24 | 2014-03-25 | Dsm Ip Assets B.V. | Compositions |
JP2010510266A (en) * | 2006-11-24 | 2010-04-02 | ディーエスエム アイピー アセッツ ビー.ブイ. | Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory and / or joint disorders |
JP2010514740A (en) * | 2006-12-28 | 2010-05-06 | ラボラトワール エクスパンシアンス | Composition for dermatological use comprising quinoa grain extract |
FR2942960A1 (en) * | 2006-12-28 | 2010-09-17 | Expanscience Lab | COMPOSITION COMPRISING AN EXTRACT OF QUINOA SEEDS |
FR2910815A1 (en) * | 2006-12-28 | 2008-07-04 | Expanscience Sa Lab | Composition, useful to prepare dermatological composition or functional food, to prevent and treat e.g. irritative, inflammatory or allergic diseases, comprises quinoa seed extract, where the extract is peptidic and osidic/liquid extract |
AU2007341237B2 (en) * | 2006-12-28 | 2013-05-09 | Laboratoires Expanscience | Composition containing a quinoa grain extract for dermatological use |
WO2008080974A1 (en) * | 2006-12-28 | 2008-07-10 | Laboratoires Expanscience | Composition containing a quinoa grain extract for dematological use |
US9125879B2 (en) | 2006-12-28 | 2015-09-08 | Laboratoires Expanscience | Composition containing a quinoa extract for dermatological use |
CN101573129B (en) * | 2006-12-28 | 2012-02-22 | 科学发展实验室 | Composition containing a quinoa grain extract for dematological use |
JP2014177498A (en) * | 2007-02-13 | 2014-09-25 | Legacy Healthcare Ltd | Method for controlling and/or stabilizing conditions which affect skin |
US9844503B2 (en) | 2007-04-19 | 2017-12-19 | Mary Kay Inc. | Magnolia extract containing compositions |
US9622965B2 (en) | 2007-04-19 | 2017-04-18 | Mary Kay Inc. | Magnolia extract containing compositions |
US9668964B1 (en) | 2007-04-19 | 2017-06-06 | Mary Kay Inc. | Magnolia extract containing compositions |
US9101555B1 (en) | 2007-04-19 | 2015-08-11 | Mary Kay Inc. | Magnolia extract containing compositions |
US10434056B2 (en) | 2007-04-19 | 2019-10-08 | Mary Kay Inc. | Magnolia extract containing compositions |
US11660259B2 (en) | 2007-04-19 | 2023-05-30 | Mary Kay Inc. | Magnolia extract containing compositions |
US11045403B2 (en) | 2007-04-19 | 2021-06-29 | Belaj Innovations Llc | Magnolia extract containing compositions |
US20100209407A1 (en) * | 2007-06-06 | 2010-08-19 | Basf Beauty Care Solutions France S.A.S. | Mc-1r, mc-2r, and/or mu opioid receptors modulation |
DE102007032662A1 (en) * | 2007-07-13 | 2009-01-22 | Beiersdorf Ag | Formulation for protecting skin aging caused by intrinsic or extrinsic factors, and for treating itching skin and atopic eczema, has apiogalacturonan or apiogalacturonan containing extract of Zostera marina and one or multiple hydrocolloids |
FR2918881A1 (en) * | 2007-07-18 | 2009-01-23 | Seppic Sa | Use of Parsnip extract as an agent for preparing the drug to prevent the formation of new fat in human body, in a cosmetic composition comprising a medium |
KR101474216B1 (en) | 2007-09-19 | 2014-12-18 | 코스맥스 주식회사 | Cosmetic compositions used for antiaging and antiwrinkle |
WO2009056614A1 (en) * | 2007-10-30 | 2009-05-07 | Chiracon Gmbh | Vegetable biocatalysts for the production of optically-active hydroxy compounds |
WO2009121168A1 (en) * | 2008-04-01 | 2009-10-08 | Biopharmacopae Design International Inc. | Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection |
FR2933294A1 (en) * | 2008-07-01 | 2010-01-08 | Limousine D Applic Biolog Dite | Cosmetic use of at least one extract from plant of Chenopodium genus as active ingredient in cosmetic composition to improve and/or strengthen skin barrier function, and to increase synthesis of enzymes acting on epidermal lipids synthesis |
US9040104B2 (en) | 2008-07-25 | 2015-05-26 | Mary Kay Inc. | Compositions comprising Docynia delavajy extract and/or Elaeagnus lancelotus extract |
US9808417B2 (en) | 2008-07-25 | 2017-11-07 | Mary Kay Inc. | Compositions comprising Docynia delavajy extract and/or Elaeagnus lancelotus extract |
US9498427B2 (en) | 2008-07-25 | 2016-11-22 | Mary Kay Inc. | Compositions comprising Elaeagnus lancelotus extract |
US8137714B2 (en) | 2008-07-25 | 2012-03-20 | Mary Kay Inc. | Compositions comprising docynia delavajy extract and/or Elaeagnus lancelotus extract |
CN101411469B (en) * | 2008-12-02 | 2012-06-06 | 富力 | Potentilla anserina extract food as well as processing technique and uses thereof |
EP2216074A1 (en) | 2009-02-07 | 2010-08-11 | Cognis IP Management GmbH | Dolichos biflorus extract for use in cosmetic skin treatment |
EP2218455A1 (en) | 2009-02-07 | 2010-08-18 | Cognis IP Management GmbH | Dolichos biflorus extract for use in therapeutic skin treatment |
US10953058B2 (en) | 2009-04-27 | 2021-03-23 | Mary Kay Inc. | Botanical formulations |
US8440237B2 (en) | 2009-04-27 | 2013-05-14 | Mary Kay Inc. | Botanical anti-acne formulations |
US11638735B2 (en) | 2009-04-27 | 2023-05-02 | Mary Kay Inc. | Botanical formulations |
US10682381B2 (en) | 2009-04-27 | 2020-06-16 | Mary Kay Inc. | Botanical formulations |
US9561198B2 (en) | 2009-04-27 | 2017-02-07 | Mary Kay Inc. | Botanical formulations |
US8481090B2 (en) | 2009-04-27 | 2013-07-09 | Mary Kay Inc. | Botanical formulations |
US8747926B2 (en) | 2009-04-27 | 2014-06-10 | Mary Kay Inc. | Botanical formulations |
KR101201921B1 (en) * | 2010-02-02 | 2012-11-15 | (주)에이씨티 | Slimming cosmetic compositions containing fagopyrum tataricym sprout extracts and preparing method thereof |
FR2941373A1 (en) * | 2010-04-09 | 2010-07-30 | Clarins Lab | Use of Thymus citriodorus extract in cosmetic composition or for preparing dermatological composition to stimulate the synthesis of elastin microfibril interface located protein, and prevent and reduce the release of skin due to pregnancy |
KR101147657B1 (en) | 2010-06-15 | 2012-05-23 | (주)에이씨티 | Slimming cosmetic compositions containing natural complex extract and preparing method thereof |
ITMI20101833A1 (en) * | 2010-10-08 | 2012-04-09 | Velleja Res Srl | METHOD FOR THE PREPARATION OF TOTAL EXTRACTS FROM MEDICINAL OR FOOD PLANTS VIA FRACTIONAL EXTRACTION |
RU2627848C2 (en) * | 2010-12-10 | 2017-08-14 | Роде Фарма С.Р.Л. | Method for active molecules extraction from natural resins and their application |
WO2012076977A1 (en) * | 2010-12-10 | 2012-06-14 | Rode Pharma S.R.L. | Method of extracting active molecules from natural resins and use thereof |
ITMI20102318A1 (en) * | 2010-12-17 | 2012-06-18 | Orsola Valeria Urzi | USE OF AN EXTRACT OF SOLANUM MELONGENA L. FOR THE TREATMENT OF WARTS |
EP2633887A1 (en) * | 2011-11-29 | 2013-09-04 | Henkel AG&Co. KGAA | Novel agent combination for efficient anti-wrinkle effect |
US9861573B2 (en) | 2011-12-19 | 2018-01-09 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
US11865202B2 (en) | 2011-12-19 | 2024-01-09 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
US9138401B2 (en) | 2011-12-19 | 2015-09-22 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
US10780041B2 (en) | 2011-12-19 | 2020-09-22 | Mary Kay Inc. | Combination of plant extracts to improve skin tone |
WO2015031971A2 (en) | 2013-09-09 | 2015-03-12 | Natura Cosméticos S.A. | A composition comprising guaçatonga extract and aroeira extract/ use thereof and a method for preventing and/or treating signals caused by skin aging |
US10966917B2 (en) | 2013-09-09 | 2021-04-06 | Natura Cosméticos S.A. | Composition comprising guaçatonga extract and aroeira extract, use thereof and a method for preventing and/or treating signals caused by skin aging |
US10500152B2 (en) | 2014-03-10 | 2019-12-10 | Mary Kay Inc. | Skin lightening compositions |
EP3135341A1 (en) | 2015-08-27 | 2017-03-01 | Latvijas Universitate | Cosmetic skin whitening compositions containing extracts derived from in vitro propagated hypericum hirsutum |
WO2018121973A1 (en) | 2016-12-30 | 2018-07-05 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | Composition comprising a plant extract of the specie hedychium coronarium, for use in a method for treatment of the human body by therapy |
EP3342465A1 (en) | 2016-12-30 | 2018-07-04 | Bayer Consumer Care AG | Hedychium extract and compositions thereof and their use in the treatment of skin affected by harmful environmental influences |
WO2019000067A1 (en) * | 2017-06-30 | 2019-01-03 | Natura Cosméticos S.A. | Skin tone-correcting cosmetic composition, use of a cosmetic composition and method for correcting the skin tone in an urban environment |
KR102141095B1 (en) | 2017-07-21 | 2020-08-05 | 티씨아이 코 엘티디 | Use of Mimosa pudica extracts for manufacture of composition for inhibiting MMP2 gene expression and collagen degradation |
KR20190050927A (en) * | 2017-07-21 | 2019-05-14 | 티씨아이 코 엘티디 | Use of Mimosa pudica extracts for manufacture of composition for inhibiting MMP2 gene expression and collagen degradation |
WO2019110887A1 (en) | 2017-12-08 | 2019-06-13 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | Novel method for reducing the effects of blue-light-induced stress on the skin |
CN108739873A (en) * | 2018-07-13 | 2018-11-06 | 李�杰 | A kind of auxiliary treatment tinea pedis uses insole cleaning solution |
CN110455951A (en) * | 2019-08-19 | 2019-11-15 | 中国农业科学院烟草研究所 | A kind of Tobacco Plastid Pigment analysis method |
CN110455951B (en) * | 2019-08-19 | 2023-10-10 | 中国农业科学院烟草研究所 | Tobacco plastid pigment analysis method |
DE102019212644A1 (en) * | 2019-08-23 | 2021-02-25 | Beiersdorf Ag | Use of bay leaf extract for the care or treatment of diabetic skin and / or aged skin |
CN112552387A (en) * | 2020-12-31 | 2021-03-26 | 山西大学 | Anti-tumor active protein of day lily and preparation method and application thereof |
CN112552387B (en) * | 2020-12-31 | 2022-11-11 | 山西大学 | Anti-tumor active protein of day lily and preparation method and application thereof |
WO2022153337A1 (en) * | 2021-01-16 | 2022-07-21 | Diabliss Consumer Products Pvt Ltd | A nutraceuticals formulation with an enhanced organoleptic properties used for skin care |
CN114470868A (en) * | 2022-02-22 | 2022-05-13 | 瑞昌市渝瑞实业有限公司 | Method and system for separating allantoin from yam mucus and method for preparing skin lotion |
CN115177570A (en) * | 2022-08-17 | 2022-10-14 | 科乐美(广州)生物科技有限公司 | Composition with soothing and repairing effects and preparation method and application thereof |
CN115177570B (en) * | 2022-08-17 | 2023-09-12 | 科乐美(广州)生物科技有限公司 | Composition with relieving and repairing effects and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1819356A1 (en) | 2007-08-22 |
US20110311661A1 (en) | 2011-12-22 |
CA2629529A1 (en) | 2006-05-26 |
JP2008520588A (en) | 2008-06-19 |
EP1819356A4 (en) | 2010-07-07 |
US20070122492A1 (en) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110311661A1 (en) | Plant Extracts and Dermatological Uses Thereof | |
US9364508B2 (en) | Inhibitors of extracellular proteases | |
US20090263516A1 (en) | Plant Extract Composition and Their Use to Modulate Cellular Activity | |
WO2012129683A1 (en) | Extracts from plants of the tsuga genus and uses thereof in the treatment of skin disorders | |
US20090004302A1 (en) | Methods and Therapeutic Compositions Comprising Plant Extracts for the Treatment of Cancer | |
ES2605823T3 (en) | Cosmetic | |
CN101855235A (en) | Protective skin care tetrapeptides | |
KR102281774B1 (en) | Composition for enhancing skin condition having skin regeneration and anti-inflammation effect | |
ES2537346T3 (en) | Proteasome activating peptide hydrolysates and compositions containing them | |
ES2942766T3 (en) | Ceiba flower extract and cosmetic, pharmaceutical or dermatological compositions containing it | |
Park et al. | Anti-photoaging effects of Angelica acutiloba root ethanol extract in human dermal fibroblasts | |
Zhao et al. | Lycium barbarum glycoconjugates: effect on human skin and cultured dermal fibroblasts | |
JP2011510908A (en) | Use of an effective agent for stimulating the expression of FN3K and / or FN3KRP for inhibiting skin aging | |
KR100431170B1 (en) | Compositions for Dental Clinic Comprising Extracts of Plant | |
US20140093596A1 (en) | Extracts from plants of the tsuga genus and uses thereof in the treatment of inflammation, irritation and/or infection | |
Benaiges et al. | Study of the refirming effect of a plant complex | |
CA2437259A1 (en) | Plant extracts and compositions comprising extracellular protease inhibitors | |
JP4643800B2 (en) | Protease inhibitor | |
KR102097723B1 (en) | Cosmetic composition for antioxidant, whitening, wrinkle and moisturizing | |
KR101856034B1 (en) | A composition for treating dermatitis comprising Atriplex hortensis extract and use thereof | |
CA2358158A1 (en) | Elastase inhibitors | |
WO2023175531A1 (en) | Protein hydrolysates of azuki beans and cosmetic uses thereof | |
KR20110052037A (en) | Composition containing natural extract that alleviates itch and atopic dermatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007122492 Country of ref document: US Ref document number: 10533025 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007541592 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 10533025 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004822419 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004822419 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2629529 Country of ref document: CA |